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INTRODUCTION

Papillomaviruses are a group of highly specialized,
transmissible, host and target specific DNA viruses which
infect the squamous epithelia and cause benign and
occasionally, malignant hyperplastic, papillomatous and/or
verrucous proliferations in skin and mucosa of a wide range
of animals and humans. 1 • 2 • 3
In vertebrate animals, papillomaviruses produce
papillomas in the skin of the rabbits which either regress,
persist or undergo malignant transformation. 4 Also, they
have the ability to stimulate the dermal fibroblasts
inducing formation of fibroblastic tumors of the brain,
polyploid tumors of the urinary bladder in cattle, sarcomalike tumors in the skin of the horse, connective tissue
tumors (fibromas, fibrosarcomas, chondromas) in hamsters and
fibromas in a type of mice. 5 In the oral cavity of
vertebrate animals, the papillomavirus is known to cause
oral papillomas in dogs, which might progress to squamous
cell carcinomas. 6 The bovine papillomavirus type 4 causes
alimentary tract papillomatosis in cattle which might become
malignant, if fed with braken fern 7 or immunosuppressed
with azathioprine. 8
In humans, papillomaviruses have been identified in

2

numerous proliferative disorders including active keratosis,
bowenoid papulosis, carcinomas of penis and vulva, cervical
intraepithelial dysplasias, condyloma acuminata,
epidermodysplasia verruciformis, kerathoacanthomas, low
grade epithelial dysplasias, melanomas, skin warts, squamous
and verrucous carcinomas (Bushke-Lowenstein tumor). In the
oral cavity, human papillomaviruses have been identified in
condyloma acuminatum, epithelial dysplasias, papillomas,
warts, focal epithelial hyperplasia, laryngeal papillomas,
"hairy" leukoplakias, leukoplakias, lichen planus, squamous
and verrucous carcinomas. 9 • 10 • 11
There are more than 60 types of human papillomavirus
(HPV) identified so far and more than 10 have been
identified in oral lesions. 12 The type of human
papillomavirus determines the histology of the lesion, the
quantity of virus production and its malignant
transformation. 13
The oral squamous papilloma is a generic name that
includes papillary and verruca! epithelial growths. The
squamous papilloma is the most common benign epithelial
tumor of the oral cavity, although some investigators regard
it as potentially pre-malignant, that can occur at any age,
but mainly in the third through the fifth decades. Any
region of the oral mucosa might be affected, but the most
common sites are the hard-soft palate-uvula complex, dorsum
and lateral tongue borders and lips.
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Clinically, the oral squamous papilloma appears as a
painless, white or pink small (the majority measures 25 to
30 mm in diameter), usually well circumscribed,
pedunculated, exophytic growth with a granular or
cauliflower-like surface. Histologically, the oral squamous
papilloma consists of many long, thin finger-like
projections of stratified squamous epithelium extending
above the surface of the mucosa with overlying
ortho/parakeratin, supported by a central fibrovascular
connective tissue core, containing an inflammatory
infiltrate. In 80% of the cases, it may have secondary and
tertiary branchings that are covered by orthokeratin or
parakeratin or both. The essential feature is a
proliferation of the spinous cells in a papillary pattern.
Mitotic activity is prevalent and variable levels of
cellular atypia are present. Koilocytosis of the epithelial
cells in the upper layers may be found

which is thought to

be indicative of viral infection. Koilocytes are cells where
the cytoplasm have suffered vacuolation and as a consequence
the nuclei appear as sorrounded by an halo or empty space.
The human papillomavirus is an etiologic agent of

~he

oral

squamous papilloma, HPV types 2, 6, 11 and 16 have been
related to these lesions.
Differential diagnosis of the oral squamous papillomas
should be made with oral condyloma acuminata and oral
verruca vulgaris, since clinical and histological
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similarities exist, making it difficult to differentiate
among them.
Clinically, the oral condyloma acuminatum is a
painless, soft, sessile, sexually transmitted viral
papillomatous lesion. The color is similar as or lighter
than the surrounding tissue. Rare in the oral cavity, it is
mostly seen in adults but also has been observed in children
who have been sexually abused. The sex partner will have
similar lesions in such case.
Histologically, the oral condyloma acuminatum exhibits broad
papillary folds with bulbous appearing rete ridges and
parakeratin crypts. The stratified squamous epithelium is
often parakeratinized but it may also be non-keratinized.
The upper spinous cell layer shows koilocytotic changes,
there is acanthosis and sometimes ballooning type of nuclear
degeneration as seen in focal epithelial hyperplasia.
Human papillomaviruses are the etiologic agents of condyloma
acuminatum. HPV types 6, 11, and 16 have been associated
with these lesions.
Clinically, the oral verruca vulgaris is a painless,
papillary lesion with white surface projections due to
keratin production. It may be undistinguishable from
papilloma. While common in skin of children and young
adults, it is uncommon intraorally. When present in oral
mucosa, the verruca vulgaris is mainly located on the palate
followed by the alveolus, gingiva, tongue, commissures and
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buccal mucosa. They exhibit varied clinical presentations
from focal exophytic lesions to multiple or spreading
verrucous lesions.
Histologically, the oral verruca vulgaris may present three
different types of patterns:
1. Acropapilloform, which consists of both angulated and
rounded papillomatous projections and abrupt cupped
margins. It is the most common pattern.
2. Acroform, which consists of acutely angulated verrucous
projections with discrete margins. It is the second
common pattern.
3. Cryptoform, which consists of bulbous acanthotic
invaginations, cornified crypts and discrete margins. It
is the least common of the variants.
The majority of the oral verruca vulgaris cases, present
both ortho and parakeratin. In some cases, koilocytes might
be seen in the granular and upper spinous cell layer, where
they can appear as small, vacuolated cells with pyknotic
nuclei or as larger, pale cells with small dark nuclei.
The human papillomaviruses are the etiologic agents of the
oral verruca vulgaris. HPV types 2 and 4 have been
associated with these lesions .14,1s,1s,11,1a,1s,20,21,22
The methods used until now for the detection of HPV
infection of cells are:
1. Hematoxylin-eosin stain, used for the observation of
histomorphologic changes present in tissues such as
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koilocytes and other cellular/nuclear atypias. Performed
on fixed tissues mounted on slides. Method not sensitive
for the detection of HPV.
2. Electron microscope, used for the observation of viral
particles but viral particles must be assembled.
Performed on fixed tissues mounted on slides. Method not
as sensitive as melecular genetics.
3. Immunoperoxidase stain of HPV antigen, used for the
observation of viral proteins. Performed on fixed tissues
mounted on slides. Method not as sensitive as molecular
genetics.
4. Southern blotting, used for the observation of cleaved
viral DNA subjected to electrophoresis, then hybridized.
Requires fresh or fresh-frozen specimen; sensitivity of
detection about 10 5 -10 6 copies of the genome; labor
intensive. Research tool, most reliable method for HPV
typing.
5. Dot blot hybridization, used to observe uncleaved
denatured viral DNA blotted onto membranes, then
hybridized. Requires fresh or frozen specimen;
sensitivity of detection similar to Southern
hybridization; difficult to discriminate weak signal
from background. Research tool for screening of HPV
types.
6. DNA "in situ" hybridization, used to observe viral DNA
localized to cells on sections using probes. Can be
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performed on fixed tissues; sensitivity of detection
variable; labor intensive. Research tool,
commercial kits available.
7. Polymerase chain reaction, is used to observe viral DNA
fragments amplified, but not localized to specific cells.
Performed on fresh or fresh-frozen specimens as well as
in fixed specimens. Sensitivity of detection 10 to 100;
potential for false-positive results because the test can
pick up even low-level contamination. Research tool, the
most sensitive technique, contamination problems,
rapid.23,24
The objectives of this investigation were:
First, to detect HPV DNA in oral squamous papillomas by
the use of "in situ" hybridization, which localizes specific
nucleic acids, DNA or RNA, in this case DNA sequences,
within the cells of tissue specimens. This was accomplished
by using wide spectrum and type specific probes. The wide
spectrum probe (WSP) targets genomic DNA of HPV types 6, 11,
16, 18, 30, 31, 33, 35, 45, 51 and 52 but does not

distinguish among them. The type specific probes (TSP)
target genomic DNA of HPV types 6, 11, 16, 18, 31 and 33
individually.
The "in situ" hybridization method was selected for this
investigation since it preserves the morphology of the
tissue, thus allowing to associate abnormal morphology with
HPV infection and to visualize the stratum in the epithelium
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where HPV DNA is located which is not possible with the
other techniques mentioned above.
Eleven of the HPV types targeted by the wide spectrum and
specific probes have been implicated in different types of
epithelial lesions:
HPV type 6 have been detected in cervical
intraepithelial neoplasia, genital warts (condyloma
acuminatum), laryngeal papillomas, oral
warts/papillomas, verrucous carcinoma (BuschkeLOwenstein tumor), vulvar carcinoma.
HPV type 11 in cervical epithelial neoplasia, genital
warts, laryngeal papillomas, oral papillomas, penile
carcinomas.
HPV type 16 in cancers of the anogenital region, highgrade intraepithelial lesions, lung carcinoma, oral
carcinoma, oral hyperkeratotic lesions, oral mucosa.
HPV type 18 in carcinoma of cervix and penis, invasive
carcinomas of the anogential region, macular lesions of
epidermodysplasia verruciformis.
HPV type 30 in laryngeal carcinomas.
HPV type 31 in carcinoma of cervix and high-grade
intraepithelial lesions of the anogenital region.
HPV type 33 in Bowenoid papulosis, carcinoma of cervix,
cervical intraepithelial neoplasias.
HPV type 35 in carcinoma of cervix, cervical
intraepithelial neoplasias.
HPV type 45 in genital warts, invasive carcinoma of the
cervix.
HPV types 51 and 52 in high-grade intraepithelial
lesions of the cervix. 25
One hundred papilloma specimens were first assayed by
the Avidin-Biotin-Peroxidase Complex for
immunohistochemistry technique which detects HPV

ant~gen.

The papillomas that yielded positive results with the use of
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antibodies to HPV proteins were assayed with the wide
spectrum probe. And in turn, those specimens that yielded
positive for HPV DNA with the Wide Spectrum Probe, were each
in turn assayed with all the type specific probes
individually.
The inununohistochemistry technique was used as a method of
selection of the papillomas to be tested with the Wide
Spectrum Probe, although the absence of HPV antigen does not
rule out the presence of HPV DNA. 26
Second, to establish "a risk profile for malignancy",
in order to determine which lesions have the potential for
becoming malignant according to the type of HPV present.
This profile would be based on the following criteria:
1.

"Low risk" lesions are those induced by HPV types
6, 11, 42, 43 and 44. These types have very
low potential for malignant transformation.

2.

"Intermediate risk" lesions are those induced by
HPV types 31, 33, 35, 51, 52 and 58. These types
might or not induce malignant transformation.

3.

"High risk" lesions are those induced by HPV types
16, 18, 45 and 56. These types have a high
potential for malignant transformation. 27

Third, to establish the location of HPV DNA in the
epithelium, since it is usually found in the nuclei of
keratinocytes in the stratum granulosum and stratum
corneum. 28 But, could it also be found in the basal fayer?
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Fourth, to determine which HPV type is present in each
papilloma specimen, due to the fact that each papilloma
could be infected with more than one type of HPV DNA.
Fifth, to compare histomorphologically the papillomas
which express HPV DNA and those papillomas which do not
express HPV DNA, based on the following criteria:
1. Presence or absence of orthokeratin or parakeratin
or both. Is the epithelium hyperkeratinized?
2. Presence or absence of koilocytosis.
3. Presence or absence of acanthosis.
4. Presence or absence of cellular atypia.
5. Presence or absence of basal cell layer replication.

As a result, I expected to find features characteristic
of viral infection such as: hyperkeratosis, koilocytosis,
dyskeratosis, papillomatosis and acanthosis.
And based on the findings of this investigation, a redefinition of "oral squamous papillomas" was suggested.

REVIEW OF RELATED LITERATURE

Genus Papillomaviruses of the Papovaviridae family, are
classified as such by virtue of their capsid structure and
biochemical composition. They induce tumors in skin and
mucosa and their name comes from the Latin, meaning papilla,
nipple, pustule and the Greek suffix "oma", to denote
tumor. 29 Each virus is named after its natural host in its
English or Latin form.
The "type" of papillomavirus is determined, based on the
degree of DNA homologies. In case of less than 50% crosshybridization under stringent conditions, two isolates are
considered as independent; if more than 50% crosshybridization, but incomplete, then they are considered subtypes (ex. HPV type 6b [b=subtype]). 30 When tested under
stringent conditions, the members of individual groups
cross-hybridize from less than 1% to 40%. 31 • 32 HPV types 6
and 11 which affect the mucosa, show 25% of cross
hybridization and very similar biological properties. 33 • 34
In general, the sequences of all papillomaviruses are highly
homologous, specially within El and Ll, which leads to
cross-hybridization between their DNAs under conditions of
reduced stringency. 35
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The human papillomaviruses (HPV) are small, nonenveloped, composed of icosahedral particles which contain
DNA and protein. The DNA is composed of 8000 base pairs,
circular, double-stranded, encapsulated in an outer protein
shell of 72 capsomeres, in a skew structure either lefthanded (cotton tail rabbit papillomavirus), or right-handed
(human papillomavirus). 36 After negative staining, the
capsomeres appear as hollow cylinders of equal height and
width, which are connected at their base by fibrous bridgelike structures. 37 All the genetic information is localized
on one strand. The viral genome is divided into:
a. An early region (about 4.5 kilobases [KB]), which
contains eight reading frames El-ES, which are necessary
for viral replication and transformation.
b. A late region (about 2.5 KB), composed of two Ll and L2
open reading frames, which are the potential coding
regions.
c. A regulatory or long control region (LRC), (about 1 KB),
which contains the origin of replication and the control
elements for the transcription and replication. 38
The E6 and E7 are the transforming proteins. The E7 proteins
bind to the retinoblastoma tumor suppressor gene product
(pRB), with a preference for the underphosphorylated
"active" form of pRB. The E7 proteins derived from the "high
risk" HPVs bind to pRB with a higher affinity than the E7
proteins from the "low risk" HPVs. The "high risk " HPV E6
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proteins can associate with the tumor suppressor p53 in
vitro and enhance their degradation, which presumably
accounts for the very low levels of p53 in cervical
carcinoma cell lines. The expression of E6 protein
substitutes for mutations within the p53 gene and seems to
lead to loss of functional p53. While, HPV negative
anogenital cancers show evidence of clonal somatic mutation
within p53. Suggesting that expression of a mutant p53
protein contributes to the development of HPV negative
tumors, which results in the expression of an altered p53
protein that may gain positive transforming activity, in
addition to losing wild type function. Therefore, HPV
negative cancers, are more aggressive in nature than HPV
positive cancers since they express a mutant p53. 39 • 40
The virus enters the mucosa through a loss of
continuity in the epithelium, where it infects the basal
layer. Here, the virus causes transformation of basal cells,
but do not undergo lytic replication, since basal cells are
non-permissive to viral replication. As keratinization takes
place, cells become permissive to viral replication.
Keratinocyte differentiation then, results in viral DNA
replication, synthesis of structural proteins and induction
of virus-specific cytopathic effects. In humans the
incubation period varies between 3 and 18 months. As
epithelium differentiates, there is early (non-structural)
protein synthesis and episomal DNA replication, which will
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either produce a condyloma or low grade epithelial lesion or
latent infection or integration of viral DNA into host
cellular genome (HPV types 16, 18, 31). Integration causes
inactivation of tumor suppressor genes of host cells which
accompanied by co-factors, could result in malignant
transformation. The above takes place with comcomitant
productive DNA synthesis and late (capsid) protein synthesis
with assembly of viral particles. As desquamation of
epithelium occur, cells are shed off into the environment,
which results in re-infection and transmission of the
virus. 41 • 42 But, progression of a benign papilloma to a
malignant carcinoma, is accompanied by cessation of
productive viral replication and alteration of the pattern
of keratinization. 43
HPV is transmitted through transplacental transmission,
contamination during passage of fetus through

bir~h

canal,

contact with an infected person, autoinoculation as in the
case of thumb-sucking habits, 44 sex or fomi tes. 45
Reports of congenital condyloma acuminatum, 46 juvenile
laryngeal papillomatosis, 47 presence of HPV DNA in the oral
cavity, foreskin 48 and amniotic fluid of newborn babies, 49
and the presence of HPV DNA in both cord and venous blood of
newborns babies born to mothers with HPV DNA in peripheral
blood mononuclear cells, suggest transplacental transmission
of the virus. 50 Newborns acquired laryngeal papillomas from
genital HPV infection by one of three ways: By direct
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contact, between the fetal larynx and the infected genital
tract of the mother, by transplacental transmission, or by
post-natal contact. 51
Sexual transmission results from ore-genital sex or contact
with infected partner through an abrasion in the
mucosa. 52 • 53 HPV type 16 DNA, has been detected in the
semen from male partners of women with HPV infection by the
polymerase chain reaction. The male harbored same HPV type
as the women. 54
There exists an immune response in organisms infected
by HPV, which is most evident in cases of immunosupression
which predisposes the individual to HPV infection, 55 and in
regressing warts. 56 Antibodies to E7 protein are found in
sera of about half the cases of invasive cervical carcinomas
associated with HPV-16 but less frequently in control sera
or in sera of carcinoma cases not associated with HPV-16. 57
In the treatment of HPV-induced lesions, surgical
removal is the most frequent method used. Interferons which
have general antiviral, antiproliferative and
immunomodulating effects, are also being used. In one study,
1/3 of refractory genital condylomas disappeared and an
additional 1/3 of the condylomas decreased in size but
interferons have been less effective in the treatment of
respiratory papillomas. 58 • 59 Autogenous vaccines have been
effective with variable success. It is thought that
immunization with capsid proteins (Ll and L2), may prevent

16
infection and that immunization with transforming proteins
(E6 and E7) may prevent progression to malignancy or reduce
tumor load in established cancers. The best prevention of
HPV infection, is the avoidance of high risk behavior. 60
According to the literature review between the years of
1965 to 1992, the following studies of different lesions of
the oral cavity have been conducted in order to detect the
presence of HPV in different oral lesions:
1. oral hairy leukoplakia was studied in thirty two patients
infected with human immunodeficiency virus (HIV), with light
microscope. Ultrastructural studies were conducted in 20 of
the cases, where viral particles of the human herpes virus
were detected in 17 of the cases and no HPV viral particles
were found. Immunohistochemical studies were made in 26
cases using a rabbit antiserum to papillomavirus where
nuclear positivity was observed in 25 of cases. 61
2. Eighty-eight formalin-fixed, paraffin-embedded invasive
squamous carcinomas were studied for HPV types 16 and 18related DNA sequences following in vitro gene amplication
using the polymerase chain reaction (PCR). Nine of the 25
(36%), oropharyngeal squamous carcinomas contained HPV DNA
sequences, including 4 of 10 (40%) laryngeal, 3 of 8 (38%)
buccal and 2 of 7 (29%) glossal tumors. Of the 44 cases that
contained viral DNA, HPV type 16 was detected in 41 cases
(93%) and HPV type 18 in 5 cases (11%), while both types
were found in 2 cases, (one anal and one vulvar). 62
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3. One hundred and fifty six formalin-fixed, paraffinembedded biopsies from 40 patients with surgically treated
oral squamous carcinoma were analyzed for the presence of
HPV infection by histopathologic evaluation, DNA "in situ"
hybridization and PCR. Morphologic changes suggesting
infection by HPV were found in 16 out of the 40 patients
(40%), HPV DNA was demonstrated in one of the lesions by "in
situ" hybridization, with a biotin-labelled probe, for types
6, 11, 16 and 18, and with the PCR technique, samples from
11 of the 40 patients proved to contained HPV DNA. Of these,
HPV- 6 was demonstrated in one case, HPV-16 in 9 cases, and
HPV-18 in one case. HPV DNA was exclusively detected in the
biopsies showing carcinoma tissue or its adjacent precancer
lesions. 63
4. A total of 206 benign oral mucosa! biopsy specimens were
studied by the indirect immunoperoxidase (IP-PAP) technique
to detect HPV antigens. Forty five of the 92 oral squamous
papillomas/condylomas studied were positive for the HPV
antigen. Also, 144 surgically treated benign oral lesions
(which were included in the 206 lesions listed above), were
analyzed using an DNA "in situ" hybridization technique with
a 35S-labeled HPV (radioactive), to demonstrate HPV types 6,
11, 13, and 16, in routinely processed, paraffin-embedded
biopsy specimens. HPV DNA was present in 45 of the 144
lesions, being found in 33.8% of the papilloma/condyloma
group. Fifteen of these 45 lesions also expressed HPV
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antigens. The most frequent HPV type was HPV-11,
representing 37.8% of the DNA positive lesions. HPV-16 DNA
was found in 4 of the papilloma/condyloma lesions, (from a
total of

s.

92).~

A 33-year-old immunosuppressed man, developed bowenoid

papulosis on his genitalia, velvety papules and plaques in
his mouth and invasive squamous cell carcinoma of his
tongue. All three lesions tested positive for HPV type
16.~

6. DNA biotinylated probes for HPV types 6, 11, 16, and 18

were tested in cytostin preparations of fine-needle
aspirates obtained from 5 squamous cell carcinomas of the
head and neck (four metastatic in lymph nodes and one
primary). All five carcinomas showed reactivity with probe
11, four were strongly reactive, and one also reacted weakly
with probe 16. HPV types 6 and 18 showed no reactivity. 66
7. Ten specimens from 5 patients diagnosed as fibropapilloma
were analyzed with the electron microscope. Specimens were
taken from the proliferative lesion and from the normal
sorrounding mucosa. HPV viral particles were seen in the
non-keratinized epithelial cells as spherical particles 4055 nm in diameter, mostly in the cytoplasmic matrix and
nuclei (especially on their chromatin masses), of the
intermediate and superficial layers, which did not form a
crystal array. Some viral particles were distributed in the
extracellular spaces of the intermediate layer, and they
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were hardly observed in cells of the basal/suprabasal and
prickle layers. All the membranous organelles of the
epithelial cells were devoid of viral particles. There were
no significant differences in the HPV distribution between
the cells derived from the proliferative lesions and those
derived from the surrounding normal mucosa. 67
8. Two hundred and seventeen tissue samples from various
human malignancies were examined for the presence of HPV DNA
with a low-stringency filter hybrydization technique, these
techniques were sensitive enough to crosshybridized with all
known papillomavirus DNAs, both animal and human.
Approximately, 2% of the cancers contained HPV DNA, these
included carcinomas of the lung, coecum, tongue and neck.
Thirteen of 4 cancers, contained HPV-16-related nucleotide
sequences. 68
9. Eighteen salivary gland pleomorphic adenomas, including 9
with a t(3;8) (p2l;q12) as the sole chromosome abnormality,
were tested for the presence of HPV DNA and for
rearrangements of the cellular flanking regions of a HPV-16
integration site maping to 3p21. None of the tumors
expressed HPV DNA or related sequences or rearranged allele
of the integration site. 69
10. Thirty-three cases of hairy leukoplakia in HIV-positive
\

patients were examined. Twelve out of 14 cases studied under
the electron microscope showed only herpes viral particles
but 95% of the 33 cases were positive for HPV antigen when
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studied by immunohistochemistry. 70
11. In sections of 373 formalin-fixed, paraffin-embedded
samples from benign and precancerous leukoplakias and
squamous cell carcinomas, HPV DNA was identified in 56 of
the specimens by the "in situ" hybridization technique. 71
12. Seven biopsies from carcinomas of the tongue were
analyzed for the presence of HPV sequences by Southern blot
analysis. One tumor was positive with HPV type 2 under
conditions of high stringency and two were positive for HPV
type 16. All tumors contained high copy numbers of their
respective viral DNA. The cleavage pattern of the HPV-2
positive cancer differed from the established HPV-2
prototype and one of the HPV-16 positive cancer also
differed from its prototype. 72
13. Biopsies from 40 cases of oral squamous cell carcinomas
were examined with light microscope to look for features of
HPV infection and by immunoperoxidase to detect the presence
of HPV antigen. Morphological signs of the flat-type HPV
lesion were found in 4 cases (10%), of the inverted type in
3 cases (7.5%), and of the papillomatous type in 9 cases
(22.5%). Koilocytosis was seen in most of the antigen
positive lesions, 5 of which were of the papillomatous type,
2 of the inverted type and 1 of the flat type. 73
14. Forty-five oral papillary lesions classified clinically
and histologically as condylomatous papilloma,
hyperkeratotic papilloma and oral wart were subjected to
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histopathological evaluation and tested by immunoperoxidase
for HPV group-specific antigens. HPV antigen was found in
10% of 31 condylomatous papillomas, 22% of the 9
hyperkeratotic papillomas, and 60% of 5 oral warts.
Koilocytosis of varying extend was regularly observed and
quantified. 74
15. HPV types 4, 16 and 18 were detected in biopsies of
normal and malignant human mucosa by Southern blot
hybridization and polymerase chain reaction (PCR). HPV DNA
from types 4, 16, 18 were detected in three different
carcinomas but viral DNA was only found in adjacent
dysplastic and normal tissue with PCR. The HPV-18 DNA
detected by Southern blot hybridization showed an altered
restriction pattern in region El of the viral genome;
however direct nucleotide sequencing of PCR products from
the E6 open reading frame showed no sequence alterations in
either normal or malignant samples. 75
16. Five papillomas, five leukoplakias and six carcinomas
were investigated for the presence of papilloma groupspeci f ic antigens, with genus-specific papillomavirus
antibodies and viral DNA, with cloned HPV types 11 and 16
DNA, used as probes in Southern blot hybridization at
conditions of different stringency. Four of five papillomas,
four of five leukoplakias and three of six carcinomas
reacted with HPV DNA probes and revealed some stained cells
after exposure to HPV antibodies. HPV-16 was found in one
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carcinoma and HPV-11 in another case of carcinoma. 76
17. Lesions of the oral mucosa, from 10 patients suffering
from focal epithelial hyperplasia (FEH), were studied for
the detection of HPV DNA by blot hybridization technique.
Four of the patients showed HPV type 13 DNA while the other
six patients showed a new HPV type, tentatively named HPV32. Also, oral papillomas from 14 additional patients were
analyzed, 5 of which expressed HPV DNA: HPV-6 was detected
in a condyloma and a papilloma, 2 showed uncharacterized HPV
DNAs and one showed HPV-32, the latter showing histologic
characteristics of FEH. Thus, FEH was conceived as a disease
associated with HPV types 13 and 32. 77
18. Twenty formalin-fixed, paraffin-embedded specimens of
human immunodeficiency virus (HIV) positive patients, were
evaluated for the presence of HPV genus-specific antigen,
HPV- 2/4, 6/11 and 16/18 DNA and Epstein-Barr virus (EBV),
by "in situ" hybridization. Three cases exhibited HPV
antigen in the cytopathologically altered spinous layer
keratinocytes and only one exhibited HPV types 16, 18 or
related sequences. While, 19 cases were found to harbor EBV
DNA, in the upper spinous layer koilocytes. 78
19. Seventeen oral epidermoid carcinomas, 3 oral papillomas
and 17 normal gingival tissues were tested for the presence
of HPV types 6, 11, 16 and 18 sequences, by Southern blot
hybridization. In 76.4% of the oral carcinomas and in all
the papillomas, HPV type 16 episomal sequences were
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detected. None of the samples contained HPV types 6, 11, or
18 sequences. Examination of the habits, showed that 59% of
the patients were quid chewers and 82% were smokers. 79
20. Seventy-seven tissue samples from patients with either
degree I, II, or III smokeless tobacco keratoses were
examined for the presence of HPV antigen by
immunocytochemistry. The antigen was found in sixteen
(20. 78%) cases. 80
21. "In situ" hybridization, was used to detect HPV DNA
types. Of 100 cases of benign leukoplakias, 4% of nontobacco-related and 10% of smokeless tobacco-related lesions
harbored viral sequences. Of the dysplastic lesions, 3%,
alternatively, 17% and 20% of the verrucous hyplerplasia and
verrucous carcinomas harbored HPV. 81
22. Twenty two cases of oral precancerous lesions (OPL) and
51 cases of squamous cell carcinomas (SCC), routinely
processed, paraffin-embedded biopsies were screened for the
presence of HPV DNA, with a 35S-labelled probe containing
types 6, 11, 13, 16, 18 and 30, by "in situ" hybridization.
The lesions which expressed HPV DNA were further analyzed
with the six HPV DNA probes, separately. HPV-6 was found in
one case of mild dysplasia, HPV-11 in 2 cases of mild
dysplasia, HPV-16 in 2 dysplasias and in 3 carcinomas and
HPV-18 in 1 moderate dysplasia and in 3 carcinomas. HPV
types 16 and 18 were simultaneously present in one case of
carcinoma. HPV-13 and 30 was not detected in any of the
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lesions. 82
23. Oral warts from 17 HIV-seropositive individuals were
analyzed by Southern blot. HPV-7 was found in 7 warts, HPV13 in 1, HPV-32 in 1 and HPV-18 in 1 from a total of 17 oral
warts. There was no correlation between HPV type,
histopathology and clinical apperance of the lesions
studied, except that the flat warts (FEH types), contained
HPV types 13, 18 and 32 (one of each). 83
24. One hundred and forty oral squamous cell papillomas
(SCPs) were subjected to immunoperoxidase-PAP method to
detect HPV antigen. Positive intranuclear staining was seen
in 41% of the cases, 9% showed both intranuclear and
cytoplasmic staining and 50% were negative for the
antigen. 84
25. Four oral papillomas and 7 carcinomas were studied by
"in situ" hybridization, with a HPV 16 biotinylated probe
under different stringent conditions. Subsequently, a
modified biotin-avidin-alkaline phosphatase procedure was
used to visualize virus-infected cells. Four papillomas and
4 carcinomas were found to contain HPV DNA. Positive cells
were located in superficial and intermediate cell layers in
papillomas and in keratinized zones in carcinomas. 85
26. Seventeen tissue specimens from 9 patients with oral
verrucous cancer were obtained, pre-malignant lesions and
primary and recurrent tumors were included. Samples were
tested for the presence of HPV DNA, by "in situ"
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hybridization with biotin-labelled probes. Under conditions
of low stringency (Tm-35 degrees), one pre-malignant lesion
and lesions from 2 other patients, hybridized with 3
different probes. The pre-malignant lesion also was positive
for HPV structural antigen. Under conditions of high
stringency, the lesions were each positive for HPV type
2. 86

27. Sixty-two oral condyloma acuminatum were tested. HPV
antigen was detected in 25% of the cases in the upper
spinous layer by a immunocytochemistry method, while 85% of
the cases expressed HPV types 6, 11 or related genomes, by
"in situ" hybridization under conditions of high stringency.
One case was found to harbor HPV type 2. 87
28. Eleven oral verruca vulgaris were examined for the

presence of HPV antigen by reaction with antibody to type
common antigens and detection by the Avidin-BiotinPeroxidase Complex method. The specimens were also examined
by "in situ" hybridization with biotin-labelled specific HPV
type probes. Six of the 11 specimens were positive for HPV
antigen and of these 6, five hybridized to the HPV-2 probe
and one to the HPV-4 probe. 88
29. Erosive oral lichen planus (OLPe)

lesions from 20

patients were examined with 32P-labeled HPV DNA probes by
Southern blot hybridization. HPV type 11 was detected in 6
of the lesions while HPV types 6, 16 and 18 were not
detected in any of them. Also, a type-specific polymerase
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chain (PCR), reaction assay was used. With the PCR method,
HPV type 11 was detected in 8 of the samples, HPV-6 in 5
samples and HPV-16 in 3 samples. 89
30. DNA extracted from a odontogenic keratocyst was assayed
for the presence of HPV type 16 using Sou_thern blot
hybridization. The HPV type 16 DNA sequences detected were
different from the prototype HPV-16. 90
31. Eighteen cases of focal epithelial hyperplasia (FEH),
were investigated for the presence of HPV antigen by
immunohistochemistry and to detect the presence of HPV types
1, 6, 11, 13, 16, 18 and 32 DNA, by "in situ" hybridization
employing biotinylated probes. Seven of the cases (39%),
expresed HPV group specific antigen while 15 cases (83%),
expressed HPV DNA. Nine cases (60 %), expressed HPV-32, five
cases (33%), expressed HPV-13 and one case (7%) expressed
HPV-11. Two specimens on different sites from the same
patient expressed the same type of virus and one patient
had, in addition to FEH, a squamous papilloma demonstrating
the same type of virus. 91
32. Two oral lesions, one from the lower lip, the other from
the buccal mucosa, from a 30-year-old HIV-positive and
immunosuppressed man, were examined by Southern blot
hybridization. Under low stringency, both lesions hybridized
with a probe coktail comprising HPV types 6, 11, 16, 18, 31
and

33 DNA. Under high stringency, the lip lesion, proved

to contain HPV-7, which also was confirmed by "in situ"
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hybridization. The buccal lesion was weakly positive with
types 11 and 13, but the restriction patterns with Pst I and
Bam HI did not fit with the HPVs known so far. Cloning of
this new type of HPV is under way. 92
33. Seventeen cases of focal epithelial hyperpasia (FEH)
were investigated by the use of "in situ" hybridization
using biotinylated probes of HPV types 1, 6, 11, 13, 16, 18
and 32 DNA. Ten cases were positive for HPV type 13 and 6
cases were positive for type 32 DNA. One case showed doubled
infection with types 13 and 32 DNA. 93
34. Five focal epithelial hyperplasia (FEH) specimens from 4
patients were evaluated for the presence of HPV DNA by
Southern blot hybridization. FEH lesions from 3 patients
that shared a familial relationship demonstrated HPV-13 DNA
sequences or a closely related sub-type and similar clinical
features. The other patient harbored sequences very similar
to HPV-32. 94
35. Biopsies from 9 oral papillomatous lesions were analyzed
by Southern blot analysis with 32p-labelled cellular DNA, to
detect HPV types 1 to 19 and 21 to 26 DNA sequences. Of the
three cases diagnosed as focal epithelial hyperplasia, 2
contained HPV-6 related sequences and one HPV-11. One tongue
base papilloma and one papilloma of the palate, contained
HPV-11. Of the remainding lesions, 2 contained HPV-6. 95
36. Twenty-one papillomas, 23 ordinary benign keratoses. 13
smokeless tobacco keratoses, 10 verrucous hyperplasias, 10

28
verrucous carcinomas, 17 squamous cell carcinomas, 3
epithelial dysplasias and 6 lichen planus, were evaluated
for HPV types 6/11, 16/18, 31/33/35, with biotinylated
doubled-stranded DNA probes. Sixty-two per cent (13/21), of
the papillomas were positive for HPV DNA, being the
strongest reactivity for types 6/11. Of the 13 cases, 10
also showed some reactivity with types 16/18 and 31/33/35.
None of the other lesions showed HPV DNA. 96
37. Twenty representative papillomas were evaluated for the
presence of papilloma genus-specific antigen by
immunoperoxidase technique and for HPV types 2, 4, 6 and 11
by "in situ" hybridization, with biotinylated full-length,
doubled-stranded DNA probes. Only one case exhibited antigen
reactivity. Seven cases (35%), yielded positive for HPV-6 or
11 and one exhibited a dual infection with HPV types 2 and
6. 97

38. Forty nine cases of primary verrucous or squamous cell
carcinoma were examined by Southern blot hybridization to
detect HPV types 2, 6, 11, 13, 16, 18, and 32.
Approximately, 60% of carcinomas particularly of the mouth,
tongue, pharynx, piriform sinus and larynx, were positive
for episomal viral DNA of HPV types 6, 11, 16 or 18. The
remainding 30 carcinomas, were examined by polymerase chain
reaction amplification assay, for DNA of HPV types 6, 11, 16
and 18, twenty-seven of which were positive for types 16 or
18 DNAs. 98
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39. The sensitivity of detection of HPV DNA in pre-malignant
and malignant oral lesions between "in situ" hybridization
(ISH) and polymerase chain reaction (PCR), was compared.
With both methods, HPV DNA was found in 4 of 24 cases of
epithelial dysplasia, 4 of 14 cases of verrucous hyperplasia
and 1 of 10 cases of squamous cell carcinoma. The 10 cases
of smokeless tobacco keratoses and 3 cases of verrucous
carcinoma studied were all negative for HPV DNA. Only a
single case that was positive by PCR was negative by ISH.
Also, the PCR demonstrated the presence of HPV-16 infection
in one case, which hybridized most intensively with the
probes for types 31/33/35 in the ISH. 99
40. Thirty-two surgically treated, paraffin oral lesions
were tested by "in situ" hybridization to detect HPV types
6, 11 and 16. A total of 10 lesions express HPV antigen,
which were found in 4 of 7 squamous cell papillomas, in 2 of
2 classic condylomas, in 2 of 10 papillary hyperplasias and
in 2 of 3 leukoplakia lesions. Two of the squamous cell
papillomas contained HPV 6 DNA and 4 contained HPV 11 DNA.
One of the condyloma contained both, type 6 and 11 DNA
while the other contained only type 11 DNA alone. Both the
antigen-positive papillary hyperplasias and leukoplakias
contained type 6 DNA. HPV type 16 was found in one lichen
pl anus and one of the 2 squamous cell carcinomas. 100
41. Fifty radomly selected oral squamous papillomas were
tested with the peroxidase-antiperoxidase technique to
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detect HPV antigens. HPV-type 1 antigen was found in 2 of
the papillomas. 101
42. One hundred and five oral lesions were analyzed by "in
situ" hybridization with biotinylated DNA probes for HPV
types 6 and 11; 16 and 18; 31, 33 and 35. Positive
hybridization signals were found in 26 specimens and only
HPV types 6/11 was detected (24.8%). HPV DNA occurred in
100% of the condyloma acuminatum and verruca vulgaris, in
13.3% of the squamous papillomas, 10% of
hyperkeratotic/acanthotic lesions and 0% of malignant and
pre-malignant lesions. The tongue (19.1%) and the labial
epithelium (17.1%) were infected most frequently. Nuclear
staining was seen mostly in koilocytes. 102
43. Samples from oral, sinus, pharynx and larynx lesions
were tested under less stringent (25% formamide, 42 degrees
C) and stringent (50% formamide, 42 degrees C) conditions.
Three samples (laryngeal papillomas) from 10 benign tumors
and 3 of 30 malignant tumors, contained HPV-related
sequences. The 3 laryngeal papillomas contained HPV types
11, 6 and 11 or 6, respectively. In the malignant tumors,
neither the typical restriction pattern of HPV DNA or viral
antigen was detected, suggesting that subgenomic fragments
remained integrated in the host cell. 103
44. A series of 191 oral mucosal tumors were analyzed by
indirect immunoperoxidase IP-PAP technique for the presence
of HPV structural proteins, of epithelial dysplasia and for
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cellular composition (B and T lymphocytes, mononuclear
phagocytes,[MPS cell]), of their local inflamatory cell
infiltrates using ANAE (acid alpha-naphthyl acetate
esterase). HPV structural proteins were disclosed in 85% of
focal epithelial hyperplasia (FEH), 75% of condyloma
acuminatum (CA) and 41% of squamous cell papillomas (SQP).
Mild dysplasia was found in 20% of both CA and SQP and
moderate dysplasia was found in 12% of the CA. B cell
infiltrate was also more predominant in cases of CA and
SQP.104
45. One hundred one patients, 66 female and 35 male, with

genital condylomata underwent an oral cavity examination.
Ninety-nine (99%) practice oral sex and 91 out of these
underwent oral biopsies with a diagnosis of condyloma in 48%
of 101 specimens collected. Of these 8 of 91 (9%) oral
lesions were suspected by naked-eye and on colposcopic
examination, 83 of 91 patients were suspected of having oral
condyloma. Of these 83 patients, 38 (46%) were confirmed
histologically, thus a total of 46 patients with genital
condyloma also exhibited oral condyloma and 38 of these 46
patients had condylomas not visible clinically. Twenty
cytological oral samples were also collected for DNA filter
"in situ" hybridization analysis. HPV DNA genital types were
observed in 45% (9/20) of all oral scrapings studied and all
were confirmed histologically • 105
46. Twenty-five oral hairy leukoplakia (OHL)

lesions from 35
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HIV-infected patients stained with antibody to
papillomavirus common structural antigens. HPV DNA was
detected in 10 of 18 OHL specimens and in 6 of 10 normal
buccal mucosa specimens.

Epstein-Barr virus (EBV) was also

being tested in this study.

The results indicate that HPV

can be found regularly in histologically normal mucosa . 106
47. A white spongeous nevus was assayed by Southern blot
hybridization for the presence of DNA sequences homologous
of HPV types 1, 2, 4, 6, 11, 13, 16 and 18. Only HPV-16
homologous DNA sequences were detected at a copy number of
approximately 200 to 250 genome copies per diploid cell. The
viral DNA sequences did not appear to be integrated into the
host cell chromosome. 107
48. Lesions from twelve patients with recurrent respiratory
papillomatosis were analyzed for the presence of HPV DNA, by
the ViraPap/ViraType hybridization procedure. Biopsies were
obtained from the respiratory papillomas and nondiseased
sites (NOS) of the respiratory tract. Fifty percent of the
patients with papilloma specimens typed positive (6 of 12)
and 40% of the patients typed positive in one or more
biopsies from the NOS (4 of 10). No oncogenic HPV types
16/18 or 31/33/35 were detected and only patients with
multiple, not isolated, papilloma involvement were found to
harbor HPV DNA in NOS. Eighty percent of patients with HPV
infected NOS, required a shorter (no more than 3 months)
treatment interval, compared to 20% of those without HPV
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infected NOS. These results showed that HPV infection
frequently persists in adjacent, clinically normal sites,
and suggested that the extend of NDS involment may predict
both the extent of disease and the likelihood of
recurrence. 108
49. Sixteen paraffin-embeded biopsy specimens of

nasopharyngeal carcinoma (eight anaplastic and eight well
differentiated squamous types), were examined for the
presence of HPV types 16 and 18 by polymerase chain
reaction. HPV DNA was not detected in any of the
specimens. 109

so.

A

peripheral ameloblastoma was studied by "in situ"

hybridization. Results were positive for HPV types 16/18 but
negative for types 6/11 DNA. 110
51. Twenty-four cases of tongue squamous-cell carcinoma

(SCC) were analyzed by dot-blot hybridization technique and
polymerase chain reaction method. HPV DNA were detected in 8
cases. One poorly differentiated grade III specimens
contained both HPV types 16 and 18; seven other cases
contained HPV-16 DNA. 111
52. Sixty formalin-fixed, paraffin-embedded carcinomas

arising from the nasal cavities (NC) and paranasal sinuses
were analyzed by using polymerase chain reaction. In cases
of squamous cell carcinoma (SCC), (n=49), the authors also
compared the clinical features of patients with HPV-positive
and HPV-negative results, to determine the clinical
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significance of HPV in

sec. HPV types 16 and 18 DNA were

detected in 7 of the 49 cases (14%) of

sec. In the other

histologic types of carcinomas (n=ll), neither type was
detected. No significant differences in the clinical
features were observed between the HPV-positive and HPVnegative

scc. 112

53. Eight sinonasal carcinomas (one adeno carcinoma, two
undifferentiated nasopharyngeal carcinomas and five squamous
cell carcinomas) were investigated by "in situ"
hybridization and polymerase chain reaction (PCR), for HPV
types 6, 11, 16, 18 and 33. All eight cases were negative by
"in situ" hybridization, while one case was positive for HPV
type 6 by PCR. The HPV DNA positive case was an invasive
papillary squamous cell carcinoma of the maxillary
sinus. 113
54. Forty benign histologically suspicious of HPV infection
were analyzed with ViraType (Life Technologies, Inc. [LT])
and Pathogene (Enzo Diagnostics, Inc. [ED]), "in situ"
hybridization kits for HPV DNA detection in oral tissue. The
purpose of this study was to compare the sensitivity of both
kits. Specimens were hybridized with DNA probes specific for
HPV types 6/11, 16/18 and 31/33/35 [LT], and HPV types 6/11,
16/18 and 31/33/51 [ED]. Positive hybridization reactions
were seen for HPV DNA type 6/11 only and more often in the
LT (20/40; ED=12/40), probed specimens. HPV DNA sequences
were seen in 100% condyloma acuminata (13/13), 100% verruca
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vulgaris (4/4) and 13% of the squamous papilloma, with the
LT system. The ED system, yielded positive signals in 77% of
condyloma acuminata (10/13), 25% verruca vulgaris (1/4) and
4.4% squamous

papillomas (1/23). 114

ss. A case of verruca vulgaris in the larynx of a 37-yearold woman was analyzed using the inunnunohistochemistry
method, "in situ" hybridization and electron microscope.
Papillomavirus capsid antigen, HPV types 6 and 11 DNA and
viral particles were detected. 115

HISTOMORPHOLOGICAL DESCRIPTION OF HPV
WIDESPECTRUM POSITIVE AND NEGATIVE PAPILLOMAS
CASE NO. 1277-92: Parakeratotic, acanthotic stratified
squamous epithelium disposed in papillary projections with
replication of the basal cell layer and supported by a
fibrous stroma. Koilocytes are present in the stratum
granulosum. BPV-1 positive, WS negative.
CASE NO. 1227-92: Parakeratotic, acanthotic stratified
squamous epithelial ridges disposed in papillary projections
with replication of the basal cell layer which exhibits
hyperchromatic nuclei and mitotic figures and supported by a
fibrovascular stroma. Few koilocytes are present in the
stratum granulosum. BPV-1 positive, WS positive.
CASE NO. 1093-92: Orthokeratotic, acanthotic stratified
squamous epithelial ridges disposed in papillary projections
with replication of the basal cell layer and supported by a
perivascular stroma. BPV-1 positive, WS negative.
CASE NO. 1090-92: Parakeratotic, acanthotic stratified
squamous epithelial ridges disposed in papillary folds with
replication of the basal cell layer and supported by a
fibrovascular stroma. Koilocytes are present in the stratum
granulosum and upper stratum spinosum. BPV-1 negative, WS
negative.
36
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CASE NO. 717-92: Hyperparakeratotic, acanthotic stratified

squamous epithelial ridges which curve centrally, exhibits a
granular layer and is supported by a fibrous stroma.
Koilocytes are present in stratum spinosum. BPV-1 positive,
WS negative.
CASE NO. 567-92: Orthokeratotic, stratified squamous

epithelium disposed in papillary projections with basal and
suprabasal cell layer mitotic activity and supported by a
fibrovascular stroma. Koilocytes are present in stratum
granulosum and upper stratum spinosum. BPV-1 positive, WS
negative.
CASE NO. 564-92: Parakeratotic, acanthotic stratified

squamous epithelium disposed in papillary projections with
replication of the basal cell layer, supported by a fibrous
stroma. Koilocytes are present in stratum granulosum. BPV-1
positive, WS positive.
CASE NO. 492-92: Parakeratotic, acanthotic stratified

squamous epithelium disposed in papillary projections, basal
cell layer replication with mitotic activity in suprabasal
and

basal cell layers, supported by a fibrovascular stroma.

BPV-1 positive, WS positive.
CASE NO: 461-92: Orthokeratotic, acanthotic stratified

squamous epithelial ridges disposed in papillary projections
with replication of the basal cell layer and supported by a
fibrous stroma. Koilocytes are present in the upper stratum
granulosum. BPV-1 positive, WS negative.
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CASE NO. 236-92: Parakeratotic, acanthotic stratified

squamous epithelium disposed in papillary projections with
replication of the basal cell layer and supported by a
fibrovascular stroma. Koilocytes are present in stratum
granulosum and stratum spinosum. BPV-1 positive, WS
positive.
CASE NO. 214-92: Parakeratotic, acanthotic stratified

squamous epithelium disposed in papillary projections with
replication of the basal cell layer and a f ibrovascular
supporting stroma. BPV-1 positive, WS positive.
CASE NO. 1065-90: Hyperparakeratotic, acanthotic stratified

squamous epithelium disposed in papillary projections with
replication of the basal cell layer and supported by
hyalinized fibrous vascular cores of stroma. Koilocytes are
present in stratum granulosum. BPV-1 positive, WS negative.
CASE NO. 799-90: Hyperparakeratotic, acanthotic stratified

squamous epithelium disposed in papillary projections with
replication of the basal cell layer and a fibrovascular
supporting stroma. Koilocytes are present in stratum
granulosum and spinosum. BPV-1 positive, WS positive.
CASE NO. 670-90: Hyperparakeratotic, acanthotic stratified

squamous epithelial ridges disposed in papillary projections
with mitotic activity and replication of the basal cell
layer and a fibrovascular supporting stroma. Koilocytes are
present in stratum granulosum and upper stratum spinosum.
BPV-1 positive, WS positive.
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CASE NO. 464-90: Hyperortho-parakeratotic, acanthotic

stratified epithelial ridges disposed in papillary
projections with replication of the basal cell layer and a
fibrovascular supporting stroma. Koilocytes are present in
stratum spinosum. BPV-1 positive,

ws

negative.

CASE NO. 242-90: Hyperparakeratotic, acanthotic stratified

squamous epithelial fused ridges, obliterating the stromal
rete pegs with replication of the basal cell layer.
Acanthosis is remarkable. Koilocytes are present in stratum
spinosum. BPV-positive, WS positive.
CASE NO. 1067-89: Hyperorthokeratotic, acanthotic stratified

squamous epithelium disposed in sharp papillary projections
with replication of the basal cell layer and a fibrous
supporting stroma. Many large koilocytes are present in
stratum granulosum. BPV-1 positive,

ws

positive.

CASE NO. 869-89: Parakeratotic, acanthotic stratified

squamous epithelium disposed in papillary projections with
replication of the basal cell layer and a fibrous supporting
stroma. Koilocytes are present in stratum spinosum. BPV-1
positive, WS positive.
CASE NO. 780-89: Parakeratotic, acanthotic stratified

squamous epithelium showing papillary hyperplasia, with
replication of the basal cell layer and a dense fibrous
supporting stroma. Few koilocytes are present in stratum
granulosum. BPV-1 positive,

ws

positive.
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CASE NO. 734-89: Orthokeratotic, acanthotic stratified

squamous epithelial ridges disposed in papillary projections
with basal cell replication and a fibrovascular supporting
stroma. Many large koilocytes are present in stratum
granulosum and spinosum. BPV-1 positive, WS positive.
CASE NO. 713-89: Hyperparakeratotic, acanthotic stratified

squamous epithelial attenuated ridges disposed in short
papillary projections with replication of a hyperchromatic
basal cell layer, mitotic activity in the basal and
suprabasal cell layers and a fibrous supporting stroma.
Koilocytes are present in stratum spinosum. BPV-1 positive,
WS negative
CASE NO. 674-89: orthokeratotic, acanthotic stratified

squamous epithelial sharp, fused ridges disposed in
papillary folds and supported by a fibrous stroma.
Koilocytes are present in stratum spinosum. BPV-1 positive,
WS positive.
CASE NO. 657-89: Parakeratotic, acanthotic stratified

squamous epithelium disposed in papillary projections with
replication of the basal cell layer and a f ibrovascular
supporting stroma. Koilocytes are present in stratum
spinosum. BPV-1 positive, WS positive.
CASE NO: 645-89: Orthoparakeratotic, acanthotic stratified

squamous epithelium disposed in sharp papillary projections
with replication of the basal cell layer and a fibrous
supporting stroma. BPV-1 positive, WS positive.
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CASB NO. 637-89: Parakeratotic, acanthotic stratified

squamous epithelium disposed in papillary projections with
basal cell replication and a fibrous supporting stroma. Many
koilocytes are present in stratum granulosum and spinosum.
BPV-1 positive, WS positive.
CASB NO: 285-89: Hyperorthokeratotic, acanthotic stratified

squamous epithelium disposed in papillary projections with
basal cell layer replication and a fibrous supporting
stroma. Many large koilocytes are present in stratum
granulosum and spinosum. BPV-1 positive, WS positive.
CASB NO. 174-89: Parakeratotic, acanthotic, stratified

squamous epithelium disposed in papillary projections with
replication of the basal cell layer and a fibrovascular
supporting stroma. BPV-1 positive, WS negative.
CASB NO. 131-89: Parakeratotic, acanthotic stratified

squamous epithelium with a slight corrugated surface,
replication of the basal cell layer and supported by a
fibrovascular lamina propia with projecting connective
tissue pegs, deep to which are neurovascular bundles and
interstitial

fibrous tissue. Large koilocytes are present

in stratum spinosum. BPV-1 positive, WS positive.
CASB NO. 71-89: Parakeratotic, acanthotic stratified

squamous epithelium disposed in papillary projectios with
replication of the basal cell layer and a f ibrovascular
supporting stroma. Koilocytes are present in stratum
granulosum and spinosum. BPV-1 positive, WS positive.
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CASE NO. 970-88: Hyperorthokeratotic, acanthotic stratified

squamous epithelium disposed in papillary projections with
replication of the basal cell layer and a f ibrovascular
supporting stroma. Koilocytes are present in stratum
granulosum. BPV-1 positive,

ws

positive.

CASE NO. 934-88: Parakeratotic, acanthotic stratified

squamous epithelial broad ridges disposed in papillary
projections with frequent mitotic activity and replication
of the basal cell layer, supported by a delicate
fibrovascular stroma. Few koilocytes are present in stratum
granulosum. BPV-1 positive, WS positive.
CASE NO: 1076-87: Parakeratotic, acanthotic hyperplastic

stratified squamous epithelial broad fuse ridges with
mitotically active basal and suprabasal cells and a fibrous
supporting stroma. Koilocytes are present in stratum
granulosum. BPV-1 positive , WS negative.
CASE NO. 735-87: Para-orthokeratic, acanthotic elongated

ridges of stratified squamous epithelium with replication of
the basal cell layer and a delicate f ibrovascular stroma
supporting the capillary projections of epithelia.
Koilocytes are present in stratum granulosum and spinosum.
BPV-1 positive, WS positive.
CASE NO. 189-87: Hyperparakeratotic, acanthotic, stratified

squamous epithelium disposed in papillary projections with
basal cell replication and a mature f ibrovascular supporting
stroma. Koilocytes are present in stratum granulosum and

43

spinosum, which show chromatin material in the periphery or
poikilocytosis. BPV-1 positive, WS negative.
CASE NO. 1106-86: Parakeratotic, acanthotic, folds of

stratified squamous epithelium disposed in sharp papillary
projections with replication of the basal cell layer and a
fibrovascular supporting stroma. Koilocytes are present in
stratum granulosum and spinosum. BPV-1 positive, WS
positive.
CASE NO. 798-86: Parakeratotic, attenuated, flattened ridges

of stratified squamous epithelium with a transition to sharp
papillary folds and hyperparakeratosis with basal cell layer
replication and a supporting fibrovascular core. Huge
koilocytes are present in stratum granulosum. BPV-1
positive, WS positive.
CASE NO. 765-86: Parakeratotic, acanthotic, stratified

squamous epithelium disposed in papillary projections with
basal cell layer replication and supported by a
fibrovascular stroma showing neurovascular bundles. Slight
reactive hyperplasia is seen with a whorling pattern of a
benign dyskeratosis near the superficial surface of the
differentiating epithelium. Koilocytes are present in
stratum granulosum and spinosum. BPV-1 positive, WS
positive.
CASE NO. 578-86: Hyperparakeratotic, acanthotic, stratified

squamous epithelium disposed in papillary folds, with
replication of the basal cell layer, which shows compressed
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keratinocytes indicating a reactive hyperplasia and
supported by a fibrovascular stroma. Koilocytes are present
in stratum spinosum and granulosum and melanocytes in the
stratum basale. BPV-1 positive, WS negative.
CASE NO. 485-86: Ortho-parakeratotic, acanthotic stratified

squamous epithelium disposed in numerous papillary ridges
with piling up of parakeratin in some areas and replication
of the basal cell layer, which shows numerous attenuated
ridge like projections into the supporting f ibrovascular
stroma. Koilocytes are present in stratum granulosum and
spinosum. BPV-1 positive, WS positive.
CASE NO. 1065-85: Parakeratotic, acanthotic, stratified

squamous epithelial elongated ridges disposed in sharp
papillary projections with replication of the basal cell
layer and a fibrovascular supporting stroma. BPV-1 positive,

ws

negative.

CASE NO. 962-85: Ortho-parakeratotic, acanthotic, stratified

squamous broad, fused epithelial ridges, disposed in
papillary projections with replication of the basal cell
layer and a fibrovascular supporting stroma. Large
koilocytes present in the stratum granulosum, some with
pyknotic nuclei. BPV-1 positive, WS positive.
CASE NO. 902-85: Hyperparakeratotic, stratified squamous

epithelium disposed in sharp papillary folds and supported
by a fibrovascular stroma. Koilocytes are present in
stratum granulosum and spinosum. BPV-1 positive, WS
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positive.
CASB NO. 892-85: Orthokeratotic, acanthotic, stratified

squamous epithelium disposed in papillary folds with
replication of the basal cell layer and a mature
fibrovascular supporting stroma. BPV-1 positive, WS
negative.
CASE NO. 816A-85: Ortho-parakeratotic, acanthotic,

stratified squamous epithelium disposed in papillary
projections with replication of the basal cell layer which
appears columnar or cuboidal and palisading as the
suprabasal cell layer shows slight variation of the
orientation, supported by a loosely arranged mucoid
connective tissue containing numerous vascular channels.
Basal and suprabasal cells show frequent morphologically
normal mitotic figures. Few localized koilocytes are present
in stratum granulosum. BPV-1 positive, WS positive.
CASE NO. 816B-85: Parakeratotic, acanthotic, stratified

squamous reactive hyperplastic epithelial ridges with basal
and suprabasal cell replication and a fibrovascular
supporting stroma. As the papillary projections arise in a
branching manner, the surface of the epithelium shows orthoparakeratinization. One area of the mucosa shows mucoid-like
loosely arranged fibrous connective tissue. Many koilocytes
are present in stratum granulosum and spinosum. BPV-1
positive, WS positive.
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CASE NO.

782-85: Parakeratotic, acanthotic, stratified

squamous broad and narrow, sharp, elongated epithelial
ridges disposed in papillary projections with basal cell
layer replication and a fibrovascular supporting stroma.
Koilocytes are present in stratum granulosum, with a
centrally placed nucleus. BPV-1 positive, WS positive.
CASE NO. 481-85: Parakeratotic, acanthotic, stratified

squamous broad epithelial ridges disposed in narrow
papillary projections with replication of the basal cell
layer and a fibrovascular supporting stroma. The basal and
suprabasal cell show many hyperchromatic nuclei, infrequent,
but morphologically normal mitotic figures. BPV-1 positive,
WS negative.
CASE NO. 627-85: Parakeratotic, acanthotic, stratified

squamous epithelium disposed in raised papillary projections
with replication of the basal cell layer, showing occasional
morphologically normal mitotic figures and a fibrovascular
supporting stroma. BPV-1 positive, WS negative.
CASE NO. 479-85: Ortho-parakeratotic, stratified squamous

epithelium disposed in sharp papillary ridges, with
replication of the basal cell layer and a fibrous supporting
stroma. The basal and suprabasal cells have multiple
nucleoli, but few and morphologically normal mitotic
figures. Some areas show hyperkeratosis with intercellular
filaments characteristic of Candida Albicans. BPV-1
positive,

ws

positive.
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CASE NO. 268-85: Orthokeratotic, acanthotic, stratified

squamous fused, broad, epithelial ridges, supported by a
fibrovascular stroma. At one point, there rises papillary
projections of the epithelium showing hyperorthokeratosis
with long, sharp, extending epithelial ridges, supported by
a branching fibrovascular connective tissue. Koilocytes are
present in stratum granulosum and spinosum. BPV-1 positive,
WS negative.
CASE NO. 160-85: Parakeratotic, stratified squamous

epithelium disposed in sharp papillary folds and supported
by a fibrovascular stroma. Few koilocytes are present in
stratum granulosum. BPV-1 positive, WS positive.
CASE NO.

655-83: Ortho-parakeratotic, acanthotic,

stratified squamous epithelium disposed in papillary ridges,
showing converging borders and supported by a f ibrovascular
stroma. Koilocytes are present in stratum granulosum and
spinosum. BPV-1 positive, WS positive.
CASE NO. 623-82: Hyperparakeratotic, acanthotic, stratified

squamous epithelium, disposed in sharp papillary ridges with
basal cell layer replication and a f ibrovascular supporting
stroma. Koilocytes are present in stratum granulosum and
spinosum. BPV-1 positive,

ws

positive.

CASE NO. 244-82: Hyperparakeratotic, stratified squamous

epithelium disposed in sharp, papillary folds that converge
inward and supported by a f ibrovascular stroma with some
striated muscle bundles. The stratum granulosum is thick,

48

showing heavy keratin/hyaline granules. Koilocytes are
present in stratum corneum. BPV-1 positive, WS positive.
CASE HO. 153-82: Hyperparakeratotic, acanthotic, stratified

squamous broad, fused epithelial ridges disposed in
papillary projections with replication of the basal cell
layer and a fibrovascular supporting stroma. BPV-1 positive,

ws

positive.

CASE HO. 143-82: Hyperparakeratotic, acanthotic, broad,

fused ridges, disposed in sharp, papillary folds with basal
cell replication and a fibrous supporting stroma. The
stratum spinosum shows multiple nucleolar like inclusions
within the nucleus of the cells. BPV-1 positive,

ws

negative.
CASE HO. 728-81: Hyperparakeratotic, stratified squamous

long, sharp epithelial ridges with plexiform pattern with
basal cell layer replication and a mature fibrovascular
supporting stroma. Many of the epithelial cells show
characteristic nuclear vesiculation with residual single or
multiple nucleoli-like structures resembling inclusions. The
stratum spinosum shows areas of cytolysis with loss of the
entire epithelial cell at sites containing infiltrating
monocytes and neutrophils. Koilocytes are present in the
stratum granulosum. BPV-1 positive, WS negative.
CASE HO. 200-80: Hyperparakeratotic, acanthotic stratified

squamous epithelial ridges disposed in papillary projections
and supported by a mature fibrovascular stroma. The basal
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cell layer shows some crowding of the epithelium, nuclear
edema and prominent nucleoli. The stratum spinosum shows
ocassional benign dyskeratotic cells and koilocytes with
contraction of the nucleus towards the cell membrane and
prominent multiple nucleoli. BPV-1 positive,

ws

positive.

CASE HO. 165-79: Hyperparakeratotic, acanthotic stratified

epithelium disposed in deep papillary folds and supported by
a fibrovascular stroma. BPV-1 positive, WS negative.
CASE HO. 213-78: Hyperortho-parakeratotic, acanthotic,

stratified squamous epithelium disposed in short papillary
folds and supported by a fibrous stroma with mucous glands.
The basal cell layer shows slight lymphocyte infiltration
and hydropic degeneration. The basement membrane is
thickened, but in some areas ill-defined due to lymphocytic
infiltration. BPV-1 positive, WS negative.
CASE HO. 155-78: Hyperparakeratotic, acanthotic, stratified

squamous epithelium disposed in sharp papillary folds with
basal cell layer replication and a mature f ibrovascular
supporting stroma. Few koilocytes are present in stratum
granulosum. BPV-1 positive, WS positive.
CASE HO. 315-75: Hyperorthokeratotic, acanthotic, stratified

squamous epithelium disposed in papillary folds and
supported by a mature, dense, fibrovascular stroma. BPV-1
positive, WS negative.
CASE HO. 557-70: Hyperparakeratotic, stratified squamous

epithelium disposed in many papillary folds with basal cell
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layer replication and a fibrous supporting stroma. Few
koilocytes are present in the stratum granulosum. BPV-1
positive, WS negative.

MATERIALS AND METHODS

I. AVIDIN-BIOTIN-PEROXIDASE COMPLEX FOR IMMUNOHISTOCHEMISTRY
PRINCIPLE

The method is based on antigen-antibody reactions in
order to detect the location of viral proteins in the cells
of formalin-fixed, paraffin-embedded oral squamous papilloma
specimens mounted on microscope slides. The technique
involves the use of a primary antibody to react with the
tissue antigenic sites, a biotin-labeled secondary antibody
against immunoglobulin of the primary species (IgG or IgM),
followed by the addition of a freshly prepared complex of
biotin-labeled horseradish peroxidase (HRP) and modified
egg-white avidin.
The primary antibody is the rabbit anti-bovine
papillomavirus type 1 (BPV-1) which was obtained by the
immunization of a rabbit with bovine papillomavirus type 1
collected from cutaneous fibropapillomas of cattle. BPV-1 is
a readily available source of large quantities of
papillomavirus. The antiserum obtained when BPV-1 is used as
an antigen is less likely to give false reactions with
endogenous intranuclear proteins and DNA in human tissue
than is the antiserum derived from human papillomavirus
51
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(HPV). The virus was treated with 0.24M 2-mercaptoethanol
and 1% sodium dodecyl sulfate (SOS), heated to 68°C for 2
minutes, diluted with three volumes of saline and mixed with
an equal volume of Freund's complete adjuvant. A rabbit was
cutaneously inoculated with the above purified, previously
characterized BPV-1 with 480, 240 and 120 mg of virus
protein at days

o, 15 and 28. The rabbit was bled at day 38.

This hyperimmune serum (anti-BPV-1 [SOS]) is reactive with
PV positive cutaneous and mucosal papillomas from a variety
of species, (human, dog, cow, rabbit, deer, and horse). This
cross reaction is due to the presence of genus-specific,
common antigenic determinants in the major capsid proteins
of papillomaviruses. 116
The biotin-labeling of anti-rabbit IgG (secondary
antibody) and peroxidase was accomplished with the
incorporation of biotin moieties into immunoglobulin (Ig) or
peroxidase (PO) molecules by the use of biotinyl-N-hydroxysuccinimide (BNHS). Biotinylation of Ig and PO improves
sensitivity and reduces time by increasing the availability
of biotin-binding sites and improving the ability to bind
avidin molecules in the avidin-biotin-peroxidase complex.
This is due to the great affinity of avidin, a 68,000
molecular weight glycoprotein found in egg white, for
biotin, a small vitamin molecule, one mole of avidin binds
up to four moles of biotin with a dissociation constant of
10-15M. During the formation of the avidin-biotin-peroxidase
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biotin, a small vitamin molecule, one mole of avidin binds
up to four moles of biotin with a dissociation constant of
10-15M. During the formation of the avidin-biotin-peroxidase
complex, avidin acts as a bridge between biotin-labeled
peroxidase and at the same time biotin-labeled peroxidase
molecules, which contain several biotin moities, serve as a
link between the avidin molecules. Consequently, a "lattice"
complex containing several peroxidase molecules is likely
formed. Binding of this complex to the biotin moities
associated with the secondary antibody results in a high
staining intensity. 117 Visualization of the viral proteins
is accomplished by the histochemical peroxidation of
diaminobenz idine. 118
INTERPRETATION OF STAINING

Staining occured predominantly intranuclear in a focal
or diffuse pattern. Perinuclear cytoplasmic staining of
koilocytotic cells was also seen in the nuclei and
cytoplasm. The positive signals appeared predominantly, as
brown or dark brown staining of nuclei in koilocytotic
cells, in a focal or diffuse pattern, although, cytoplasmic
staining was also seen.
MATERIALS
SPECIMENS

One hundred lesions subjected to routine hematoxylin
and eosin stain and diagnosed as "oral squamous papillomas",
were retrieved from the files of the Oral Pathology
Laboratory, Dental School, Loyola University Medical Center.
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The specimens were formalin-fixed, paraffin-embedded, from
the years of 1970 to 1992 and were categorized based on
their size as:
a. Good size specimens, 3 or more mm.
b. Moderate size specimens, 2 or 3mm.
c. Poor sized specimens, less than 1 mm.
Only those categorized as good and moderate sized specimens
were selected for the purpose of this investigation.
REAGENTS

1. Phosphate-buffered saline {PBS), lOX concentration
Sodium phosphate monobasic monohydrate

50 g

Sodium phosphate dibasic, anhydrous

240 g

Sodium chloride

280 g

Tween 20
Deionized water, to make:

4 mL
4 L

Diluted 1:10 with water to make the working solution.
2. 1% Albumin-saline {PBS-BSA)
Bovine serum albumin, fraction V

1 g

Tween 20

0.1 mL

PBS

100 mL

Mixed and added, as preservative:
Sodium azide

50 nig

3. Primary antibody in PBS/BSA containing
1% normal goat serum Rabbit Anti-Bovine
Papillomavirus {BPV-1)

30 µ,L

Normal goat serum

60 µ,L
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PBS/BSA

6 mL

Sodium chloride

120 mg

Albumin, fraction v, source bovine blood

120 mg

Primary antibody dilution obtained was of 1:200.
The above concentration was used for a batch of 30 slides.
The amount of solution to be prepared depends on the amount
of slides being processed. Albumin and sodium chloride were
used in order to decrease background.
4. Streptavidin-horseradish peroxidase kits
Obtain from Kirkegaard-Perry Laboratories
Cat. No. 71-00-18 (mouse primary)
71-00-19 (rabbit primary)
Each kit contained blocking serum, biotinylated secondary
antibody and streptavidin-HPR conjugate.
5. Diaminobenzidine (DAB) substrate
a. Buffer
Ammonium acetate

3.85 g

Deionized water

900 mL

Added citric acid, 10%, to obtain pH 5.5.
Added water to make 1 L. Store at 4°

c.

b. Substrate solution
Two tablets (lOmg each) DAB (Sigma D-5905) were added
for each 50 mL of buffer at room temperature, allowed
to dissolve and filtered. Just before using, 90 µL 3%
H20 2 per 50 mL was added. After use, substrate
solution was poured into bottle containing sodium
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hypochlorite solution, treated for 27 hours and then
disposed via sink.
5. Hematoxylin
Harris-type hematoxylin solution (non-mercuric), was
obtained from Newcomer Supply (Cat. No. 1201).
6. Pepsin
One packet of Dako pepsin (Cat No. S3002), was added to
200 mL of deionized water. When dissolved, 50 mL lN HCL
was added. store at -20°c.
CONTROLS

Controls may be of several kinds:
1. A positive control (type 1), tissue specimen which is
treated together with the patient specimen and monitored
for typical appearance.
2. A negative control (type 2), for which the patient
specimen is treated as usual, but omitting the primary
antibody. Nonspecific positive reactions such as
endogenous peroxidase would be revealed in such a
control.
3. Dilution controls (type 3), in which a series of graded
dilutions of primary antibody are applied to a control
specimen to assess the performance of a particular brand
or lot of antibody in comparison to previous or expected
results.
Type 1 controls are performed, usually, with one control
slide being included per antigen tested per case.
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Representative samples are obtained, processed according to
standard protocols and tested in the procedure before used.
Type 2 controls are included in instances where increased
background might be expected to occur or in the case of
tissues bearing pigment that might be confused with reaction
product.
Type 3 controls are performed as needed and the results
recorded in a log book showing the antibody, its dilution
and any other pertinent information.
The type of control used in this investigation, were 4
micron thick sections of buffered 10% formalin-fixed,
paraffin-embedded papilloma mounted on poly-L-lysine coated
microscope slides, obtained from DAKO Corporation (Catalog
No. T1211). Positive anti-papillomavirus antigen nuclei,
were found more predominantly in stratum granulosum than in
stratum basale. Also stained are pyknotic nuclei and nuclear
breakdown products, as well as perinuclear tissue of stratum
corneum. Any non-specific background staining of
cytokeratins was ignored.
OTHER MATERIALS USED

DAKO Rabbit Anti-Bovine Papillomavirus
No.B580)
Albumin in powder
100%, 70%, 95% alcohol, and acid alcohol
Ammonia water
Concentrated normal goat serum

(BPV-1), (cat.
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Deionized water
1N HCL
Sodium chloride in powder
Xylene
Absorbent wipes
Brushes of different sizes
Coplin Jars
Covers lips
Droppers and pump for droppers
Gloves
Humidified chamber for slide incubation
Mounting medium
37°C oven and 60°C oven
Permanent ink markers
2-8°C refrigerator
Silanized microscope slides
Staining racks
Standard light microscope
Tweezers
38°C water bath
PROCEDURE

1.

3 µm sections of paraffin-embedded tissue were cut and
mounted on glass slides that have been coated with
organosilane. Water bath temperature was monitored at
38°C.

2.

Sections were air-dried at 20-37°C.
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3.

All slides were pre-heated 20-30 minutes at 60°C., then
transfered directly to xylene without cooling and
treated with three changes of xylene, 5 minutes each.

4.

Slides were rinsed in two changes of absolute alcohol.
In order to inactivate/extract endogenous peroxidase
and hemoprotein, slides were then immersed in absolute
ethanol with 0.075% HCL for 15 minutes,

(0.1 mL cone.

acid/50 mL).
5.

Sections were brought through graded alcohols (95%-70%)
to water and then to PBS. No enzyme treatment was
required.

6.

In a moist chamber, slides were covered with the
blocking reagent (normal goat serum), provided in the
kits and left at room temperature for 30 minutes.

7.

Sections were blotted quickly on filter paper and
covered

with a solution of the primary antibody in

PBS/BSA containing 1% normal goat serum. Slides were
placed back in the moist chamber and placed in the
refrigerator, the level of the chambers checked and
left incubated for 15-18 hours (or longer if needed).
8.

Incubation in antibody solutions at this and subsequent
stages was followed by washing in three changes of PBS,
5 minutes each, to remove unreacted antibody.

9.

Biotinylated antibody against IgG of the species in
which the primary antibody was prepared (prediluted or
prepared from concentrated antibody) was applied to the
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sections for 30 minutes at ambient temperature. In this
particular case goat anti-rabbit IgG was used.
10.

After washing as before, sections were covered with
streptavidin-peroxidase reagent in the moist chamber
for 30 minutes at ambient temperature.

11.

Sections were washed in PBS as before, then rinsed with
deionized water and placed in peroxidase substrate
solution (DAB) for 3 minutes in a dark chamber.

12.

After thorough washing in water, the sections were
counterstained with Harris hematoxylin for 4 minutes,
differentiated in acid alcohol (1% HCl in 70% ethanol),
blued in 0.1% ammonia water, washed in running tap
water, dehydrated, cleared and mounted in AccuMount.

DEHYDRATION PROCEDURE: 70%-95%-95%-100%-100% alcohol for 3
minutes each and three changes of xylene for 5 minutes each.

Note: The entire procedure was performed according to

protocol prepared by Robert Martinez,
(Immunohistochemistry Laboratory, Loyola University
Medical Center) and adapted to this investigation.
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II.

IN SITU HYBRIDIZATION FOR BPV TYPE WIDE SPECTRUM PROBE,
BPV TYPE SPECIFIC PROBES, POSITIVE AND NEGATIVE CONTROL
PROBES.
PRINCIPLE

The "in situ" hybridization technique is used to detect
the presence of human papillomavirus (HPV) DNA sequences
within the nuclei the epithelial cells of formalin-fixed,
paraffin-embedded, tissue sections of oral squamous
papilloma specimens, mounted on slides. The morphology of
the tissue is preserved with this technique making it
possible to relate the presence of HPV with pathologic
changes and at the same time enables the investigator to
visualize the exact location of viral DNA.
Tissue sections are first de-paraff inized and then
digested with a proteolytic enzyme, pepsin, in order to
remove proteins that mask DNA, to increase the accessibility
of HPV DNA sequences and to allow probes to permeate the
tissue sections more effectively. Next, the double-stranded
HPV DNA sequences and biotinylated probes are simultaneously
denatured at a temperature of 90°C, by placing the slides on
a heating block, the probe is allowed to hybridized the HPV
DNA sequences within the tissue specimen. A stringent wash
solution is then used to remove excess probe, and this
stringent wash solution contains a blocking agent that
blocks nonspecific binding sites on the tissue which may
otherwise react with the detection reagents. After the
stringent wash, the streptavidin alkaline phosphatase
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conjugate is used, which binds to the biotin groups on the
hybridized probe molecules. The site of hybridization is
visualized by the colorimetric reaction of the alkaline
phosphatase enzyme conjugate with its substrate, BCIP (5
bromo-4 chloro-3 indolyl phosphate) and the concomitant
reduction of NBT (nitro blue tetrazolium), this reaction
results in the deposition of an insoluble blue-purple
product at the site of hybridization.
PROBES

HPV types 6, 11, 16, 18, 31, 33, wide spectrum HPV,
positive control (human DNA) and negative control (plasmid
DNA), biotinylated DNA probes were used.
Biotinylation of the probe is accomplished through the nonradioactive labeling of the nucleic acids with biotin
(vitamin H). The biotinylated nucleotide are enzymatically
incorporated into the probe molecule by the nick translation
DNA labelling method. 119 The biotin molecule is covalently
bound to the C-5 position of the pyrimidine ring through an
allylamine linker arm in the nucleotide analogs of
deoxyuridine triphosphate and 5-(3-amino) allyl uridine
triphosphate. These analogs function as substrates for a
series of RNA or DNA polymerases in vitro. The interactions
of biotin and avidin have one of the highest binding
constant (Kcus=l0- 15 ) known. The use of streptavidin (a
modified avidin tetrameric protein) coupled (or conjugated)
to the enzymes alkaline phosphatase and peroxidase which act
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as indicator molecules, enables the detection of minute
quantities of biotin 120 in the biotinylated probes. Thus,
the highest sensitivities for the detection of biotinylated
probes are achieved by using streptavidin, which unlike
avidin exhibits very low nonspecific binding. 121
WIDE SPECTRUM HPV BIOTINYLATED DNA PROBE

This double-stranded DNA probe is a nick-translated
probe prepared from human papillomavirus (HPV) DNAs which
are cloned into plasmid DNA vectors from phage vectors. The
targets for this probe are the genomic DNAs of HPV types 6,
11, 16, 18, 30, 31, 33, 35, 45, 51 and 52. When tested at
intermediate stringency (Tm -20°C.) in a non-radioactive
Southern blot hybridization using 50 ng of cloned HPV DNA's
as targets, this probe hybridizes to the DNA of HPV types 6,
11, 16, 18, 30, 31, 33, 35, 45, 51 and 52. The probe is used
for the detection of HPV DNA in tissue specimens by "in
situ" hybridization (ISH) and when used in the recommended
ISH procedure, the probe demonstrates reactivity only with
tissues infected with HPV. 122
HPV TYPE 6 BIOTINYLATED DNA PROBE

This type-specific double-stranded DNA probe is a nicktranslated probe prepared form sub-genomic clones of human
papillomavirus (HPV) type 6 which are cloned into plasmid
vectors. The targets for this probe include regions of the
ES and L2 ORF's (open reading frames) of HPV type 6. When
tested by non-radioactive Southern blot hybridization at
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high stringency (Tm -1o·c.) against 100 ng of cloned HPV DNA
from types 6, 11, 16, 18, 30, 31, 33, 3S, 4S, Sl and S2 this
probe is specific for HPV-6 • 123
BPV TYPE 11 BIOTINYLATED DNA PROBE

This type-specific double-stranded DNA nick-translated
probe is prepared from sub-genomic clones of human
papillomavirus (HPV) type 11 which are cloned into plasmid
vectors. The targets for this probe include regions of the
ES and L2 ORF (open reading frames) of HPV 11. When tested

by non-radioactive Southern blot hybridization at high
stringency (Tm -1o·c.) against 100 ng of cloned HPV DNA from
types 6, 11, 16, 18, 30, 31, 33, 3S, 4S, Sl and S2, this
probe is specific for HPV 11. 124
BPV TYPE 16 BIOTINYLATED DNA PROBE

This type-specific double-stranded DNA nick-translated,
is prepared from sub-genomic clones of human papillomavirus
(HPV) type 16 which are cloned into plasmid vectors. The
targets for this probe include regions of the El, E2, E4,
ES, E6 and E7 ORF's (open reading frames) as well as the URR

(upstream regulatory region), of HPV type 16 when tested by
non-radioactive Southern blot hybridization at high
stringency (Tm - lO"C.) against 100 ng of cloned HPV DNA
from types 6, 11, 16, 18, 30, 31, 33, 3S, 4S, Sl and S2 this
probe is specific for HPV 16 • 125
BPV TYPE 18 BIOTINYLATED DNA PROBE

This type-specific double-stranded DNA nick-translated

6S
probe is prepared from sub-genomic clones of human
papillomavirus (HPV) type 18 which are cloned into plasmid
vectors. The targets for this probe include regions of the
E2, ES, E6, E7 and L2 ORF's (open reading frames) as well as
the URR (upstream regulatory region) of HPV type 18. When
tested by non-radioactive Southern blot hybridization at
high stringency (Tm - l0°C.) against 100 ng of cloned HPV
DNA from types 6, 11, 16, 18, 30, 31, 33, 3S, 4S, Sl and S2,
this probe is specific for HPV 18. The probe is used for the
detection of HPV type 33 DNA in tissue specimens by "in
situ" hybridization and when used in the recommended ISH
procedure the probe demonstrates reactivity only with
tissues infected with HPV 18. 126
HPV TYPE 31 B:IOTJ:NYLATED DNA PROBE

This type-specific double-stranded DNA nick-translated
probe prepared from sub-genomic clones of human
papillomavirus (HPV) type 31 which are cloned into plasmid
vectors. The targets for this probe include regions of the
E2, ES and L2 ORF's (open reading frames) as well as the URR
(upstream regulatory region) of HPV type 31. When tested by
non-radioactive Southern blot hybridization at high
stringency (Tm - l0°C.) against 100 ng of cloned HPV DNA
from types 6, 11, 16, 18, 30, 31, 33, 3S, 4S, Sl and S2,
this probe is specific for HPV 31. The probe is used for the
detection of HPV type 31 DNA in tissue specimens by "in
situ" hybridization (ISH) and when used in the recommended
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ISH procedure, the probe demonstrates reactivity only with
tissues infected HPV 31. 127
HPV TYPE 33 BIOTINYLATED DNA PROBE

This type-specific double-stranded DNA nick-translated
probe prepared from sub-genomic clones of human
papillomavirus (HPV) type 33 which are cloned into plasmid
vectors. The targets for this probe include regions of the
E2, ES, E6 and L2 ORF's (open reading frames) as well as the

URR (upstream regulatory region) of HPV type 33. When tested
by non-radioactive Southern blot hybridization at high
stringency (Tm -10°c.), against 100 ng of cloned HPV DNA
from types 6, 11, 16, 18, 30, 31, 33, 45, 51 and 52, this
probe is specific for HPV 33. The probe is used for the
detection of HPV type 33 DNA in tissue specimens by "in
situ" hybridization and when used in the recommended ISH
procedure the probe demonstrates reactivity only with
tissues infected with HPV 33 • 128
The detection sensitivity of wide spectrum and typespecific HPV probes is approximately 100 molecules of target
sequences as measured by "in situ" hybridization and as
measured with an analogous probe on HPV-infected, cultured
cells. When assayed under recommended protocol none of the
probes reacted with normal human nuclear DNA when probed by
"in situ" hybridization, or with E. Coli DNA when tested by
blot hybridization.
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POSITIVE CONTROL (HUMAN DNA) BIOTYNILATED DNA PROBE

Positive control (human DNA) biotinylated DNA probe is
a double stranded human DNA nick-translated probe prepared
from total human DNA which has been purified from cultured
human cells. This probe targets total genomic human DNA. The
probe is used for the detection of human DNA in the nuclei
of tissue specimens by "in situ" hybridization, it is only
intended for use on human tissues. The detection sensitivity
of this probe when assayed by "in situ" hybridization when
using the recommended protocol, shows most normal diploid
nuclei stained positively . 129
NEGATIVE CONTROL (PLASMID DNA) BIOTINYLATED DNA PROBE

Negative control (plasmid DNA) biotinylated DNA probe
is a double-stranded plasmid DNA nick-translated probe
prepared from pUC18 plasmid DNA which has been purified from
cultured E. Coli cells. This probe targets total plasmid DNA
from pUC18. This probe is used as a negative control to
asses the levels of background staining and non-specific
probe binding on formalin-fixed, paraffin-embedded tissue
specimens during "in situ" hybridization. This probe is
intended for use on human tissues only. When assayed by "in
situ" hybridization using the recommended protocol, no
staining was observed on normal formalin fixed, paraffinembedded tissues. 130
MATERIALS
REAGENTS

The following materials, sufficient for processing 50

68

slides, are included in the DAK09 In Situ Hybridization
Detection System K601 and K602.

Quantiy

Description

2 Bottle 2:

15 ml Stringent Wash concentrate (SOX)
containing o. 015m NaN3 •

1 Bottle 3:

15 ml Streptavidin, Alkaline Phosphatase
conjugated, in Tris buffer (lX)
containing 0.015m NaN3 •

1 Bottle 4:

15 ml BCIP/NBT substrate/chromogen
solution (lX)

1 Plastic pipette for Stringent Wash dilution
1 5 ml calibrated test tube for Stringent Wash dilution
Pepsin/HCL Digestion reagent
Tris-buffered Saline (TBS)
OTHER MATERIALS USED

Absorbent wipes
Alcohol solutions (95 and 100%)
Biotinylated probes
Covers lips
Deionized or distilled water
Gloves
90°C heating plate or oven
Humidified chamber for slide incubation
3 7°C incubator
40-60°C incubator or water bath
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Mounting medium
60°C oven
Silanized-treated microscope slides
Staining racks or coplin jars
Standard light microscope
Xylene
PREPARATION OF REAGENTS

The following reagents required preparation prior to
beginning the procedure.
A. Pepsin/HCI Digestion reagents.
This reagent is required for "in situ" procedures using
DNA hybridization on formalin-fixed tissues. Pre-measured
pepsin packets, Code No. S3002 are available from DAKO.
The entire contents of one of the pepsin packets were
dissolved in 250 ml on 0.2N hydrochloric acid. The
digestion reagents were heated at 37° C using a water
bath just prior to use. Excess solution was stored
immediately at 20°

c.

B. Tris-buffered Saline (TBS).
Pre-measured TBS packets, Code No. S3001 are available
from DAKO. The entire contents of one TBS powder were
dissolved package in 1 liter of deionized or distilled
water. The diluted solution is stable for one month a
4°C.

c.

Stringent Wash Solution.
Stringency requirements will vary depending on probe
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composition (%G + C) and the degree of homology between
probe and target sequences. Generally, a wash of
intermediate stringency should be tried first. If the
resultant background is too high, stringency should be
increased by raising the temperature of the wash; if
signal intensity is too weak, stringency should be
lowered by decreasing the wash temperature.
The chart below was used to select stringency conditions
when using nick-translated DNA probes of approximately 50 %
G + c content on formalin-fixed, paraffin-embedded tissues.
stringent wash temp.

stringency

40°C

low

50°C

medium

60°C

high

The stringent wash temperature used for the Wide Spectrum
Probe was 48°C, the same as for the positive and negative
controls that accompanied the procedure.
The stringent wash temperature used for each of the Type
Specific Probes was 58°C, the same as for the positive and
negative controls that accompanied the procedure.
The dropper tip from Bottle 2 was removed. With the use of
the plastic pipette and calibrated test tube, 1 ml of the
50X Stringent Wash concentrate (Bottle 2), was dispensed
into each 50ml of deionized water. Any unused diluted
solution was discarded. The stringent wash concentrate
provided made 1500 ml of diluted solution.
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SPECIMEN COLLECTION AND PREPARATION

The reagents and procedures used in this kit were
optimized for DNA-DNA hybridization using tissues that have
been routinely processed using buffered formalin and
embedded in paraffin.
A. Tissue processing
Fixation times in buffered formalin should be 24 hrs or
less; prolonged fixation can result in decreased specific
staining and elevated background staining. It is
recommended that fixation times be standardized to
minimize tissue variability.
In this case, tissues were formalin-fixed, paraffinembedded, but fixation times were unknown.
B. Tissue sectioning and mounting
Tissue sections were cut 3 microns thick. The aggressive
digestion and heating steps used in the DNA "in situ"
procedure require that tissue sections be well adhered to
the glass slides; slides were coated with
organosilane. The procedure for the coating of normal
slides with organosilane was as followed:
Clean slides were immersed in 2% solution of 3aminopropyl-triethoxysilane in acetone for 2 minutes.
Rinsed twice in distilled water and air dried. After
dried, coated slides were baked for 30 minutes at 60°C,
to ensure optimal adhesion of the sections to the slides
and stored at room temperature in a dust-free container.
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PROCEDURE

In Situ hybridization procedure for double-stranded DNA
probes and formalin-fixed, paraffin-embedded tissues:
Prior to beginning the procedure, the pepsin/HCI reagent was
prepared and pre-warmed to 37°C.
TBS was prepared and dispense into 4 baths of 250 ml each.
A heating block was pre-warmed to 90°C.
All instructions were read thoroughly, with particular
attention to incubation times and temperature.
A. De-paraffinization
Slides with tissue sections were warmed in a 60°C oven
for 30 minutes.
Sections were immersed in two changes of xylenes, for 5
minutes. Sections were immersed in two changes of 100%
alcohol, followed by three changes of 95% alcohol, for
one minute each. Sections were then rinsed in two changes
of deionized water for 3 minutes each.
B. Tissue Digestion
The conditions listed below were optimized for tissues
that have been fixed according to DAKO recommendations.
over-fixed tissues may require longer digestion times in
order to achieve adequate staining.
Sections were immersed in pre-warmed pepsin-HCI for 15
minutes at 37°C, (digestion conditions may need to be
tailored to the particular tissue used).
Sections were washed in two changes of distilled water
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for 5 minutes.
Slides were removed from water and excess water wiped
from around each tissue section.

c. Denaturation and Hybridization
One drop from each probe of hybridization solution was
applied to the tissue section. A coverslip was placed
over the tissue and hybridization solution, taking care
not to introduce bubbles under the coverslip.
The slides were laid on a flat heating block which had
been pre-warmed to 90°C. The slides were oriented with
the coverslips facing up and with the tissue sections
directly over the heating surface. Sections were heated
for 5 minutes at 90°C to denature the probe and target
DNA. A 90°C oven may also be used for this step; resting
the slides on a metal tray or shelf is recommended to
ensure efficient heat transfer to the slides when using
an oven.
After denatured, the slides were transfered from the
heating block to a pre-warmed humid chamber, and
incubated at 37°C to hybridize the probe to the target
DNA. The required incubation period will depend on the
probe concentration used, and may vary from one to twelve
hours. At this point the stringent wash was prepared and
pre-warmed to the appropriate temperature in a water
bath.

o.

Detection Procedure

74

The tissues can not be allowed to dry during the
detection procedure, since this would alter the
hybridization signal. The slides were removed from the
humid chamber and immersed in a TBS bath for 5 minutes.
Slides were soaked in the TBS solution in coplin jars,
until the coverslips slided off of the slides. The slides
were immersed in a fresh TBS bath for 2 minutes in coplin
jars.
The slides were immersed in the pre-warmed stringent wash
solution in coplin jars and incubated at the appropriate
temperature, (refer to page 70: Reagent Preparation) for
30 minutes. The slides were immersed in a fresh TBS bath
in coplin jars for 1 minute. The slides were removed from
the TBS and carefully excess fluid wiped off from around
the sections. The slides were placed on a level surface
and enough Streptavidin-AP reagent was applied to each
section to completely cover the tissue and incubated for
20 minutes at room temperature. The Streptavidin-AP
reagent was poured off from each slide and slides were
immersed in a fresh TBS bath for 5 minutes, in coplin
jars. The slides were removed from the TBS and carefully
excess fluid was wiped off from around the sections. The
slides were placed on a level surface and enough of the
BCIP/NBT substrate solution was applied to each section
to completely cover the tissue and the slides were
incubated in the dark at room temperature. The time
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required for substrate development will vary with target
concentration. High copy targets are usually
visualized in 60 minutes or less; low target
concentrations may necessitate the use of longer
substrate incubations. If long incubations are used, it
is recommended that the reaction be monitored each hour
to avoid over-staining. In this case the slides were
incubated for 60 minutes. The substrate solution was
poured off from each slide and slides were immersed in
deoionized water bath for 5 minutes.
In this case, slides were not counterstained or mounted in
permanent media to avoid any possibility of loss of the
positive signal and/or misinterpretation of the signal. If
desired, tissues may be counterstained by immersing slides
in Nuclear Fast Red for 1-2 minutes, followed by a rinse in
distilled water for 1 minute. And mounted with permanent
(non-aqueous) media, by immersing the slides for one minute
each in 95% and 100% alcohols followed by 1 minute in
Histoclear or xylenes. When using aqueous mounting media,
slides should be mounted directly without dehydration.
NOTES ON THE PROCEDURES

Tissue sections should not be allowed to dry out once the
hybridization procedure has been started. Sections that are
allowed to dry will exhibit elevated levels of background
staining.
The incubation times and temperatures specified in the kit
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instructions are critical for successfully using this
procedure. Any change in the procedure may result in
decreased performance of the assay.
The color of the positive signals produced by the BCIP/NBT
reaction had a purple hue, and background may be more
prominent when tissues are mounted with aqueous
mounting media.
Mounting with permanent media will result in bluer reaction
signals and very low background levels, but some signal may
be lost during the tissue dehydration and clearing steps.
In order to determine the specificity of the hybridization
reaction, a biotinylated probe of irrelevant specificity may
be used as a negative control (i.e. DAKO Negative Control
[plasmid DNA] Biotinylated DNA Probe, Code No. X1102 was
used).
A positive control probe is useful for determining the
suitability of tissue fixation for "in situ" hybridization.
DAKO Positive control (Human DNA) Biotinylated DNA probe,
Code No. XllOl, was used to demonstrate genomic DNA in the
nuclei of human tissues. The specificity of the detection
reagents can be demonstrated by carrying out the
hybridization procedure in the absence of probe; the
presence of background using this control is indicative of
either high levels of endogenous biotin in the tissue, or
nonspecific binding of the detection reagents. The latter
problem may occur if the sections are allowed to dry out
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during the detection procedure.
LIMITATIONS OF THE ASSAY

Negative results may be caused by a variety of procedure
factors, such as improper tissue fixation, mishandling of
reagents or performing incubations at improper temperatures.
Target sequences which exist only at very low copy numbers
may go undetected. In some instances, binding of
streptavidin to endogenous biotin within tissues may
contribute to high background. Liver, kidney, and highly
proliferative tissues or cells often exhibit high levels of
endogenous biotin.
The stringency of hybridization reactions is dependent upon
many parameters, including probe specificity and the
temperature and ionic strength of both hybridization and
wash solutions.
INTERPRETATION OF STAINING

Positive signals, corresponding to areas of hybridization,
appeared as blue or blue-purple regions within individual
cells of the tissue. Overdevelopment of the substrate
chromogen may result in black signals.
Counterstaining with nuclear counterstains may make the
interpretation of positive signals difficult if too much
counterstain is used. The use of hematoxylin is not
recommended, since the blue color of the positive reaction
is easily obscured by the blue counterstain. A light
counterstain of the tissue section using Nuclear Fast Red is
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recommended if additional morphological detail is desired.

Note: The entire procedure was performed according to DAKO
In Situ Hybridization Detection System for
Biotinylated Probes K601 and K602 and adapted to this
investigation.

RESULTS

As indicated in TABLE A, 63 of 100 papillomas evaluated
by the Avidin-Biotin-Peroxidase Complex method, which showed
either nuclear or nuclear and cytoplasmic staining, were
considered as positive.
Papilloma virus antigen was detected in stratum corneum in 1
case; in stratum granulosum in 35 cases; in stratum corneum
and granulosum in 7 cases; in stratum corneum and granulosum
and upper stratum spinosum in 3 cases; in stratum granulosum
and upper stratum spinosum in 17 cases.
Positivity of the staining reaction was noted as a brown to
dark brown precipitate in the nuclei and cytoplasm, but
cytoplasmic staining without nuclear staining was not taken
as positive. Labelling of the cytoplasm can occur due to
fragmentation of infected nuclei and release of virus
particles and virus-associated proteins into the cytoplasm,
or due to non-specific reactivity of cytoplasmic substances
with HPV antibodies. 131
The 63 cases that stained positively for the papilloma
virus antigen were tested by "in situ" hybridization. A wide
spectrum probe (WSP) which targets HPV DNA of types 6, 11,
16, 18, 31, 33, 30, 35, 45, 51 and 52 was used. Of these 63
specimens 39 yielded positive results under intermediate
79
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stringency (48° C).
The 39 cases that were positive with the WSP were, in
turn, tested individually, each with the type specific
probes (TSP), under conditions of high stringency (58° C),
yielding the following results, (APPENDIX C):
HPV type 6 positive, 7 papillomas.
HPV type 11 positive, 2 papillomas.
HPV type 16 positive, O papillomas.
HPV type 18 positive, 2 papillomas.
HPV type 31 positive, 10 papillomas.
HPV type 33 positive, 3 papillomas.
HPV types 6 and 11 positive, 2 papillomas.
HPV types 6 and 31 positive, 5 papillomas.
HPV types 6 and 33 positive, 1 papilloma.
HPV types 11 and 31 positive, 2 papillomas.
HPV types 18 and 33 positive, 1 papilloma.
HPV types 11, 31 and 33 positive, 1 papilloma.
HPV types non-conclusive results, 3 papillomas.
As indicated in TABLE B and APPENDIX B, the following
reactivity were seen with the TSP:
HPV type 6 probe, 15 cases were strongly positive, 5
were moderately positive and 8 weakly positive.
HPV type 11 probe, 6 cases were strongly positive, 2
were moderately positive and 1 weakly positive.
HPV type 16 probe, none of the cases were strongly
positive, 2 were moderately positive and 4 weakly
positive.
HPV type 18 probe, 2 cases were strongly positive, 1
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moderately positive and 6 weakly positive.
HPV type 31 probe, 17 cases were strongly positive, 5
moderately positive and 2 weakly positive.
HPV type 33 probe, 5 cases were strongly positive, 3
moderately positive and 7 weakly positive.
Multiple strong hybridization signals with the
following HPV type probes:
HPV type 6 and 11 probes, 2 cases.
HPV type 6 and 31 probes, 5 cases.
HPV type 6 and 33 probes, 1 case.
HPV type 11 and 31 probes, 2 cases.
HPV type 18 and 33 probes, 1 case.
HPV type 11, 31, and 33 probes, 1 case.
Two of the cases belonged to a same patient, being the two
papillomas strongly positive with HPV type 11 probe and
moderately positive with HPV type 31 probe.
Multiple moderate signals were seen in 1 case which
reacted with probe 18. Multiple weak signals were seen in 2
cases, one reacted with probes 6, 31, 18 and others with
probes 31 and 33. The results for these cases were recorded
as non-conclusive (NC).
Positivity of the staining reaction was noted as a
blue-purplish or black precipitate in the nuclei of the
infected cell. In some cases of tissues that contained high
amounts of DNA, the stain spread from the nuclei into the
surrounding spaces. However, cytoplasmic staining in the
absence of nuclear staining was not interpreted as positive.
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This was seen in 6 cases.
Positive staining occurred in cells with pyknotic ovoid
nuclei, crescent-shaped or flat elongated nuclei which could
be compressed against the cell membrane and small or
enlarged centered or wrinkled nuclei, but these
characteristic could also be seen in negative cells.
Staining intensity varied from weak (pale blue-purple)
to strong (dark blue-purple or black).
Staining patterns of nuclei were based on the following
criteria, according to Enzo PathoGene DNA Probe Assay for
Identification of Human Papillomavirus (Catalog No. PG-877),
Interpretation Guide:
a. Full nuclear staining, nucleus appeared completely filled
with stain.
b. Granular or stippled nuclear staining, nucleus appeared
filled with granules or dots.
c. Mixed nuclear staining, the nuclei of some cells appeared
fully stained, while the nuclei of others showed a
granular or stipped staining.
Reactions with the WSP were either considered positive or
negative. A weak, moderate or strong nuclear staining was
considered as positive.
Reactions for TSP were considered as positive, inconclusive
or negative based on the intensity of the hybridization
signal:
1. Positive, a strong hybridization signal, when nuclear
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staining was dark, same as control slide and a moderate
hybridization signal, when the signal was lighter than
control slide but darker than the weaker hybridization
signal.
2. Non-conclusive, only weak or moderate hybridization
signals with more than one probe.
3. Negative, absence of nuclear staining.
Nuclear staining was confined to single cells localized in
certain areas of the epithelium or clusters of cells
localized or diffused throughout the epithelium.
Weak multiple hybridization signals of the same
papilloma with different specific probes were considered
negative since according to the manufacturer (DAKO
Corporation), this may be indicative of cross reactivity
with other HPV types in the tissues which contains very high
amounts of HPV DNA. HPV type is determined in these cases by
comparison of the signal intensities resulting from the
individual probes. The strongest hybridization signal was
the one considered as positive.
Positive and negative controls showed no equivocal
results and no signs of cross hybridization.
All positive controls were strongly positive for each of the
probes.
Specimens that were strongly positive for HPV types 6,
11 and moderately positive for HPV type 16 showed nuclear
staining in cells of stratum granulosum and upper stratum
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spinosum.
Specimens that were strongly and moderately positive for HPV
type 18, staining of nuclei was confined to stratum
granulosum and spinosum in 2 cases and one case also showed
reactivity in the stratum basale.
Specimens that were positive for HPV types 31 and 33
exhibited a multi-layered pattern of reactivity, in these
cases staining was seen in stratum granulosum, spinosum and
basale.
Based on the histomorphological description, a
comparison of papillomas positive and negative with the wide
spectrum probe (WSP) showed the following results:
FEATURE

WSP POSITIVE

WSP NEGATIVE

Hyperorthokeratin

3 cases

1 cases

Hyperparakeratin

8 cases

9 cases

Hyperorthoparakertin

o cases

2 cases

Hyperpara/parakeratin

2 cases

O

Hyperortho/orthokeratin

o case

1 case

Orthokeratin

2 cases

4 cases

Orthoparakeratin

8 cases

O

cases

cases

Parakeratin

16 cases

7 cases

Acanthosis

35 cases

21 cases

Basal cell replication

34 cases

16 cases

Dyskeratosis

2 cases

O

cases

Hyperchromatic nuclei

1 case

O

cases

Koilocytosis

34 cases

14 cases
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Mitotic activity

5 cases

2 cases

Multiple nuclei

1 case

o cases

Prominent nucleoli

1 case

1 case

Koilocytosis varied from huge koilocytic cells to small
koilocytic cells which could either be localized or sparsed
through the epithelium.

DISCUSSION AND CONCLUSIONS

The main objective of this study was to detect the
presence of HPV types 6, 11, 16, 18, 31 and 33 in oral
squamous papillomas. This was accomplished through the use
of two different methods, the Avidin-Biotin-Peroxidase
Complex for the immunohistochemistry technique and "in situ"
hybridization.
Papillomavirus antigen was detected in 63% (63/100) and
HPV DNA in 61% (39/63) of the papillomas which were tested
with the Wide Spectrum Probe, while 38% (24/63), were
negative for HPV DNA.
The majority of the papillomas, were infected with HPV
type 31 DNA, 25% (10/39); followed by HPV type 6 DNA, 17%
{7/39); HPV types 6 and 31 DNA, 12% (5/39); HPV type 33 DNA,
7% (3/39), HPV type 11, 5% (2/39); HPV types 6 and 11 DNA,
5% (2/39); HPV types 11 and 31 DNA, 5% (2/39); HPV type 18
DNA, 5% (2/39);HPV types 6 and 33 DNA,(1/39): 2% HPV types
18 and 33 DNA, 2% {l/39); HPV types 11, 31 and 33 DNA, 2%
(1/39). None of the cases expressed HPV type 16 DNA and 3 of
the cases showed non-conclusive results,

{APPENDIX C).

Oral lesions with no evidence of viral antigen and/or
DNA may:
1. Be a non-viral associated tumor, a normal anatomic
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variant or a papillary hypertrophy resulting from long
standing inflamatory disease. 132
2. Be a new HPV genotype with a nucleotide sequence that
does not cross hybridize with the probes employed in this
study.
3. Represent HPV-associated lesions with a viral copy number
below that detectable by the "in situ" hybridization
technique.
4. Have been virally initiated with subsequent shedding of
infected cells through epithelial proliferations and
maturation. 133
5. Have been originally present but lost during the harsh
treatments of the procedure.
Based on the findings of this investigation, a
histomorphological description of the papillomas which
express HPV DNA and those papillomas which do not express
HPV DNA was performed, in order to establish a correlation
between histology and molecular hybridization findings.
It is believed, that papillomavirus (PV) induce changes in
the epithelium which reflect their biological behavior. PV
induced lesions display features of acanthosis, dysplasia,
dyskeratosis, hyperchromasia, hyperkeratosis, koilocytosis
and basal cell replication. These cytologic changes are
associated with virus production, which result in the death
of the infected cell as the virus multiply in the nucleus
and the level where these cytopathic changes begin is
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determined by the virus type. 134
PV affects the keratinocyte metabolism, changes in
keratin composition are seen in a variety of epidermal
disorders and these changes seem to correlate with the
degree of hyperplasia in the lesion. The most common finding
is the decrease in the relative amount of 67K keratin. 135
Acanthosis and basal cell proliferation, is thought to occur
due to the presence of HPV DNA in the basal cell layer. In
common warts, autoradiography with tritiated thymidine has
shown an increase in DNA synthesis in basal and parabasal
cells, two to three layers above the basement membrane 136
and juvenile laryngeal papillomas in parabasal cells
extending nearly to the surface.u 7 Also, basal cell
hyperplasia, is thought to be due to an early gene
expression of the HPV ocurring prior to vegetative viral DNA
synthesis. In contrast, the synthesis of viral capsid
proteins appear to be a function of late gene expression
since it occurs only in terminally differentiated squamous
cells in the superficial layers. 138
PVs seem to have a predilection for specific sites of
the epithelium rather than being specific for a particular
lesion. This tissue-specificity may reflect a requirement
for cellular factors present in keratinocytes. PV subtypes
may have evolved by adapting to different patterns of
keratinocyte differentiation found in specific
epi thel ia. 139
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HPVs 6, 11, 13, 16, 18 and 32, the types that most

commonly

infect the oral mucosa, share a degree of sequence homology
with each other and these homologous regions might play a
role in tissue-specific infection. The above might explain
the fact, that similar HPV types have been detected in
clinically and histomorphologically different lesions,
except for types 13 and 32. These types are mainly seen in
Focal Epidermal Hyperplasia, (FEH) and have only been
detected in oral mucosa and perioral skin, as well as in a
small percentage of Condyloma Acuminatum, (CA) and Squamous
Cell Papillomas (SCP). Lesions which contain HPV types 13
and 32 show FEH-like characteristics, such as hyperpara-or
hyperorthokeratosis, increased cellular density, acanthosis,
unusual rete pegs that demonstrate clubbing and horizontally
anastomosing outgrowths, koilocytes, mitosis-like nuclear
degeneration, swollen cells with ballooning type of nuclear
degeneration.
Immunoregulation plays a role in the pathogenesis of HPV
induced lesions, since they predispone the individual to
uncommon types and to develop lesions with an unusual
clinical apperance." 0
In the genital tract, proliferations induced by viral
types 6, 11 and 31, preserve characteristics of regular
differentiation pattern, the nuclei are regularly shaped and
the DNA content is tetraploid or diploid. 141 While,
proliferations caused by types 16 and 18, are characterized
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by marked nuclear atypia, regular and atypic mitotic figures
even in the upper third of the epithelial layer, an
aneuploid karyotype and a low number of koilocytotic cells
which may be entirely absent. 142 Also, they seem to regress
less and recurr more frequently than those proliferations
cause by HPV types 6 and 11. Common warts regressing more
frequently than condyloma acuminatum. In general, PV-induced
proliferations of the genital tract are caracterized by long
duration and frequent recurrence, even after surgical
removal . 143
The majority of HPV induced lesions in skin and mucosa
regress spontaneously but a certain number progress to
malignancy. HPV types 6 and 11 are considered to cause
benign lesions, while HPV types 16 and 18 are considered to
have oncogenic potential. Thus, lesions caused by these
types are considered malignant, or at least pre-malignant.
HPV type 18 seems to produce a more invasive type of lesion
than HPV type 16. Their role in neoplastic transformation is
clearly seen in Epidermodysplasia Verruciformis (EV) and
ano-geni tal carcinomas. 144 In the oral cavity, there is a
report of leukoplakias transforming into squamous cell
carcinomas. 145
The ability of certain HPV types for malignant
transformation seems to be related to two transforming
proteins encoded in their genome, which bind to the tumor
suppressor gene of the cell, providing a mechanism for HPV
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induced cervical neoplasm. 146 Or, there could be a genetic
lack or malfunction of the tumor suppressor gene, thus
allowing the virus to control the replication mechanisms of
the epithelial cells and start replicating itself. Repeated
studies have demonstrated that the majority of cervical
cancers and derived cell lines contain HPV DNA. But not all
cells infected with the virus undergo malignant
transformation because the malignant tumors are monoclonal,
while the HPV lesions are not. 147 ·1 48
In the etiology of cancer, there seems to be a need for
cofactors which act with the virus in order to produce the
malignant transformation, because usually the time elapsed
since the time of infection and the onset of cancer could be
decades. 149 In the oral cavity, such co-factors could be
alcohol, chewing tobacco, cellular mutations, heredity,
radiation, smoking and in the skin, also, sunlight. Such is
the case in EV, where skin lesions containing HPV types 5
and 8 become malignant after being exposed to sunlight.
HPV infection is transmissible and the virus is highly
contagious. Since it has no envelope, the virus is resistant
to either inactivation, freezing and dessication, therefore
remains infectious after drying . 150
The majority of the papillomas which expressed HPV DNA
with the Wide Spectrum Probe (WSP), showed parakeratin 41%
(16/39), followed by hyperparakeratin 20% (8/39) and orthoparakeratin 20% (8/39), hyperorthokeratin 7% (3/39),
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combination of hyperpara/parakeratin 5% (2/39) and
orthokeratin 5% (2/39).
Of the papillomas which did not expressed HPV DNA with the
WSP, the majority showed hyperparakeratin 37% (9/24),
followed by parakeratin 29% (7/24), orthokeratin 16% (4/24),
hyperorthoparakeratin 8% (2/24), hyperorthokeratin 4% (1/24)
and combination of hyperortho/orthokeratin 4 % (1/24).
Acanthosis was seen in 89% (35/39) of the papillomas
which expressed HPV DNA and in 87% (21/24) of the papillomas
which do not expressed HPV DNA.
Basal cell layer replication was seen in 87% (34/39) of
the papillomas which expressed HPV DNA and in 66% (16/24) of
the cases which did not expressed HPV DNA.
Dyskeratosis (benign) was only seen in 2 of the
papillomas which expressed HPV DNA 5% (2/39).
Koilocytosis was seen in 87% (34/39) of the papillomas
which expressed HPV DNA and in 58% (14/24) of the papillomas
which did not expressed HPV DNA.
Basal cell mitotic activity was seen in 12% (5/39) of
the papillomas which expressed HPV DNA and in 8% {2/24) of
the papillomas which did not expressed HPV DNA. Suprabasal
cell mitotic activity was seen in 5% (2/39), of the
papillomas which expressed HPV DNA and in 12% (3/24) of the
papillomas which did not expressed HPV DNA.
Nuclear hyperchromasia in basal cells was seen in 2%
(l/39), prominent nucleoli in basal cells were seen in 2%
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(1/39), multiple nucleoli in basal and suprabasal cells were
seen in 2% (1/39), of the papillomas which expressed HPV
DNA. Prominent nucleoli in basal cells were seen in 4%
(1/24) of the cases which did not expressed HPV DNA,
(APPENDIX D and E).
Nuclear shape varied in cells which expressed HPV DNA.
Positive staining occured in cells with pyknotic ovoid
nuclei, crescent-shaped or flat elongated nuclei which could
be compressed against the cell membrane, wrinkled nuclei and
small or large centered nuclei.
Varying degrees of papillomatosis, were seen in all
papillomas.
Thus, different forms of keratinization, acanthosis,
koilocytosis, papillomatosis, basal and suprabasal cell
replication, basal and suprabasal mitotic activity were seen
in papillomas whether or not they expressed HPV DNA.
As shown in this study, hyperkeratinization is not
pathognomonic of HPV infection. But in the oral cavity,
keratinization present in papillomas located in areas of
normally non-keratinizing epithelium such as ventral surface
of the tongue, floor of the mouth, vestibular mucosa and
tonsils, is abnormal.
Koilocytosis and parakeratinization were the most prominent
features of HPV infected papillomas. Thus, in the oral
cavity koilocytosis and parakeratinization are caracteristic
of the presence of HPV DNA, according to the results of this
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investigation.
The type of HPV determines its location in the
epithelium. HPV types 6, 11, 16 DNA were only detected in
the most superficial layers of the epithelium , while HPV
types 31 and 33 were also detected in stratum basale. HPV
type 18 DNA, was detected in one papilloma in the stratum
granulosum, spinosum and basale.
A papilloma can be infected with more than one type of
HPV based on the most recent investigation using an improved
technique for Polymerase Chain Reaction (PCR) . 151
Single infection was seen in 24 papillomas which reacted
strongly with only one probe (6, 11, 18, 31, 33). Dual
infection was seen in 11 papillomas where there was a strong
reaction with two different probes (6 and 11; 6 and 31; 6
and 33; 11 and 31; 18 and 33 ). A triple infection was seen
in a papilloma which reacted strongly with probes 11, 31 and
33, (APPENDIX A).
There were two cases of multiple weak positive signals and
one with multiple signals which were regarded as nonconclusive.
The multiple weak or moderate signals present in the same
papilloma could have been caused by:
a. Cross-hybridization between the probe and viral DNA
sequences. 152
b. Very low DNA number copies present in the specimen
weakly detected by the probe.
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c. Presence of a diferent type of virus from the type
being tested by the type specific probe (TSP) but
target by the wide spectrum probe (WSP).
d. Type of solution used to fix the tissue and fixation
times will affect the intensity of the hybridization
signal, reducing it even to undetectable levels. 153
e. Strong homology between HPVs, such in the case of
HPV types 6 and 31 that causes cross hybridization
between these two types . 154
A risk profile for malignancy could be established
according to the type of HPV present.
Papillomas infected with HPV types 6 and 11 are considered
"low risk". Although, there has been reports of laryngeal
papillomas positive for HPV type 6, progressing to
pharyngeal carcinomas, 155 but it could have been caused by
an undetected HPV, belonging to the types considered
oncogenic.
Papillomas infected with HPV types 31 and 32 are considered
"intermediate risk", and papillomas infected with HPV 16 and
18, are considered "high risk".
Typing should be done of all oral squamous papillomas
because of the oncogenic potential of some HPV types and
patients should be closely monitored. And also, because of
statitical and histopathological evidence suggesting that
condylomata which may exist as a sub-clinical PV infection
and cervical intraepithelial neoplasm (CIN), represent the
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extremes of a single disease spectrum. 156
The above could also be applied to the oral cavity. Oral
squamous papillomas (including oral condyloma acuminatum and
oral verruca vulgaris}-leukoplakia-oral verrucous
carcinomas-oral squamous carcinomas could all be part of a
same disease spectrum, since the same HPV DNA types have
been detected in these lesions.
In the oral cavity, all papillomas, whether they
exhibit the same clinical and histomorphological
caracteristics of its counterpart in the ano-genital region
(Condyloma Acuminatum} or its counterpart in the skin
(Verruca Vulgaris}, should be considered variants of the
same disease entity. Therefore, base on the findings of this
investigation and in the characteristics observed in the
majority of the cases assayed, oral squamous papillomas
could be re-defined as:
Oral squamous papillomas are composed of keratinized,
acanthotic, stratified squamous epithelial ridges, disposed
in papillary projections with basal cell layer replication
and a fibrous or fibrovascular supporting stroma. The
epithelial ridges could be elongated, short, broad, fused or
not. The papillary projections could be sharp or blunt. The
overlying epithelium is mainly parakeratinized, but it could
also be hyperparakeratinized, orthokeratinized,
hyperorthokeratinized, or a combination of paraorthokeratin. Koilocytosis, dyskeratosis, dysplasia might be
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present or not.
The diagnosis of Oral Squamous Papillomas, would be
made based on whether or not they express viral DNA and
whether or not they exhibit characteristics of Condyloma
Acuminatum or Verruca Vulgaris:
HPV DNA positive papillomas, with caracteristics of
Condyloma Acuminatum, would be diagnosed as "Oral
Squamous Papillomas of viral origen, compatible with
Condyloma Acuminatum."
HPV DNA positive papillomas, with characteristics of
Verruca Vulgaris, would be diagnosed as "Oral Squamous
Papillomas of viral origen, compatible with Verruca
Vulgaris."
HPV DNA positive papillomas, which do not present
characteristics of Condyloma Acuminatum or Verruca
Vulgaris would be diagnosed as "Oral Squamous
Papillomas of viral origin".
HPV DNA negative papillomas, would be diagnosed as
"Oral Squamous Papillomas of non-specific origin."
Based on the above re-definition, the present confusion
that exists regarding the diagnosis of oral squamous
papilloma, condyloma acuminatum, and/or verruca vulgaris
could be eliminated if all these lesions were considered as
papillomas in the oral cavity, whether they exhibit
characteristics of condyloma acuminatum or verruca vulgaris.
HPV types 6, 11, 16, 18, 31, 33 infect the oral mucosa
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as have been shown in this investigation. Whether, transient
or permanent hosts of the oral cavity, they cause papillary
lesions of the epithelium. And, as DNA hybridization
techniques for detection of HPV improve and other more
sensitive techniques develop, more oral squamous cell
papillomas will be found to harbor HPV DNA.
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TABLE A
PAPILLOMAS CASE SELECTION AND RESULTS

CASE NO.

AGE/SEX

LOCATION

BPV-1

1335-92

31/M

Hard Palate

-

1277-92

29/F

Hard Palate

+

-

1227-92

36/F

Soft Palate

+

+

1093-92

40/F

Hard Palate

+

-

1090-92

50/M

Lower Lip

+

-

996-92

40/F

Ginqiva # 8

-

717-92

12/F

Lower Lip

+

689-92

40/F

Soft Palate

-

567-92

41/M

Vermillion Lip

+

-

564-92

32/M

Lower Lip

+

+

6

492-92

28/M

Lingual Frenum

+

+

31

461-92

44/M

Buccal Mucosa

+

-

236-92

36/M

Buccal Mucosa

+

+

6

214-92

57/M

Floor Mouth

+

+

6,11

1040-90

36/M

Submax. Duct

-

1065-90

32/M

Uvula

+

-

799-90

52/F

Vermillion Lip

+

+

18,33

670-90

25/M

Buccal Mucosa

+

+

NC*

464-90

64/F

Tip Tonque

+

-

424-90

64/M

Alveolar Ridge

-

242-90

55/F

Lateral Tongue

+

+

18

1067-1-89

65/F

Buccal Mucosa

+

+

31

1060-89

29/M

Soft Palate

-

WSP

TSP

33

-

100
869-89

63/M

Lingual Fr enum

+

+

6,33

780-89

52/M

Ventral Tongue

+

+

11,31

734-89

54/M

Labial Mucosa

+

+

18

713-89

81/F

Buccal Gingiva

674-89

17/M

Gingiva

657-89

30/M

Soft Palate

+
+
+

656-89

77/M

Hard Palate

-

645-89

17/M

MGJ*

637-89

38/F

377-89

+

31

+

NC

+

+

11,31

FM-BT*

+

+

11,31,33

8/F

Unknown

-

285-89

28/F

Area # 13

+

+

33

174-89

NK*/M

Soft Palate

+

-

191-89

47/F

Tongue

-

131-89

73/M

Tip Tongue

+

129-89

NK/M

Lower Lip

-

71-89

65/F

Soft Palate

+

1050-88

32/M

Dorsal Tongue

980-88

62/F

Ventral Tongue

-

970-88

50/M

Soft Palate

934-88

53/F

834-87

+

31

+

31

+

+

6

Hard Palate

+

+

NC

10/F

Retromolar Pad

-

735-87

45/M

Dorsum Tongue

+

+

31

628-87

NK/F

Buccal Gingiva

-

189-87

51/F

Tip Tongue

+

13-87

53/M

Floor Mouth

-

1106-86

57/M

Buccal Mucosa

+

843-86

41/M

Buccal Mucosa

-

798-86

51/F

Lateral Tongue

+

789-86

56/M

Tonsil Pillar

-

765-86

55/M

Lingual Gingiva

+

+

6,31

+

31

+

6

101
798-86

51/F

Lateral Tongue

+

789-86

56/M

Tonsil Pillar

-

765-86

55/M

Lingual Gingiva

578-86

62/M

524-86

+

31

+

+

6

Uvula

+

-

25/F

Buccal Mucosa

-

485-86

25/F

Tip Tongue

+

356-86

36/M

Tuberosity

287-86

67/F

Soft Palate

-

1065-85

33/M

Unknown

+

-

962-85

41/M

Buccal Mucosa

+

+

6

902-85

NK/M

Comissure Lip

+

+

6,31

892-85

NK/M

Retromolar Pad

+

-

816-A-85

NK/M

Alveolar Ridge

+

+

11

816-B-85

NK/M

Lingual Frenum

+

+

11

782-85

49/M

Dorsum Tongue

+

+

6,31

627-85

32/F

Tip Tongue

+

-

479-85

26/M

Dorsal Tongue

+

+

481-85

63/M

Tonsilar Pillar

+

-

228-85

47/F

Tongue

+

-

341-85

41/F

Ventral Tongue

-

268-85

37/M

Hard Palate

+

-

160-85

33/M

Ventral Tongue

+

+

6

333-84

27/M

Buccal Mucosa

-

240-84

63/F

Gingiva # 2

-

698-83

54/F

Lateral Tongue

-

682-83

58/M

Dorsum Tongue

-

655-83

38/M

Mucosa Lip

+

+

6,11

623-82

60/M

Palate

+

+

31

244-82

62/F

Upper Lip

+

+

6,31

216-82

63/F

Buccal Mucosa

-

+

31

6,31

102
153-82

NK/F

Hard Palate

+

+

143-82

NK/F

Alveolar Ridqe

+

-

142-82

53/F

Alveolar Ridge

-

728-81

30/M

Mucosa Cheeck

+

620-81

NK/M

Lateral Tonque

-

387-81

35/M

Lower Lip

-

200-80

60/F

Palate

+

202-79

30/F

Hard Palate

-

165-79

38/M

Hard Palate

+

213-78

6/F

WOP*

+

193-78

42/F

Vermillion Lip

-

155-78

23/M

Lingual Frenum

+

532-77

56/M

Hard Palate

454-77

27/M

Retromolar Pad

-

410-75

25/M

FM-BT

-

315-75

NK/F

823-74

NK/M

Unknown

-

1002-70

50/M

, Lower Lip

-

785-70

5/F

Gingiva

-

557-70

56/M

Soft Palate

+

Papilla Max.

* NC: Non-conclusive
* MGJ: Muco-Gingival Junction
* FM-BT: Floor Mouth-Base Tongue
* NK: not known
* WOP: Wharton's Duct Papilla

+

33

+

31

+

-

-

6
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TABLE B
BPV TYPE SPECIFIC PROBE REACTIVITY

CASE

HPV-6

1227-92

+

564-92

+++

492-92

+

236-92

+++

214-92

+++

799-90

+

HPV-11

HPV-16

HPV-18

+
+

+++

+++
++

++
+

+

+++

+

+++

10671-89
869-89

+++

780-89

++

+++

734-89

+

+

674-89

++

657-89

++

+++

++

+

+++

+++

++

++

+

+++
++

+

++

645-89
637-89

HPV-33

+++

670-90
242-90

HPV-31

++
++

+++

+

+

+++

++

285-89

++
+++
+++

+++

131-89

+

71-89
970-88

+++

934-88

+

I

735-87

+

++

1106-86

+++

+

+++

+

+
+

+++
+++

+

104
962-85

+++

902-85

+++

+

+++

816-A-85

+++

++

816-B-85

+++

++

782-85

+++

+++

479-85

+++

+++

160-85

+++

655-83

+++

+++
+

623-82
244-82

+

+++

+++

+

+++
+++

153-82
200-80

++

155-78

+++

+

Weakly reactive

++

Moderate reactive

+++ Strongly reactive

+++
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FIGURE 1: HPV Type Wide Spectrum Positive Control
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FIGURE 2: HPV Type Wide Spectrum Positive Papilloma
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FIGURE 3: HPV Type 6 Positive Control

FIGURE 4: HPV Type 6 Positive Papilloma
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FIGURE 5: HPV Type 11 Positive Control
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FIGURE 6: HPV Type 11 Positive Papilloma
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FIGURE 7: HPV Type 18 Positive Control

•
FIGURE 8: HPV Type 18 Positive Papilloma
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FIGURE 9: HPV Type 31 Positive Control

FIGURE 10: HPV Type 31 Positive Papilloma
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APPENDIX A
HPV INFECTED PAPILLOMAS
Single Infection
NO. PAPILLOMA

HPV TYPE

7
2
0
2

6

11
16
18
31
33

10
3

Dual Infection
NO. PAPILLOMA

HPV TYPE

2
5
1
2
1

6, 11
6, 31
6, 33

11, 31
18, 33

Triple Infection
HPV TYPE

NO. PAPILLOMA

11,31,33

1

Inconclusive Infection
HPV TYPE
NC

NO. PAPILLOMA
3
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APPENDIX B
TYPE SPECIFIC PROBE REACTIVITY
HPV Type

Weak

Moderate

strong

6

8

5

15

11

1

2

6

16

4

2

0

18

6

1

2

31

2

5

17

33

7

3

5
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APPENDIX C
HPV DNA POSITIVE PAPILLOMAS
HPV Type

.Percentage

Cases

31

25%

10/39

6

17%

7/39

6, 31

12%

5/39

33

7%

3/39

NC

7%

3/39

11

5%

2/39

6, 11

5%

2/39

11, 31

5%

2/39

18

5%

2/39

6, 33

2%

1/39

18, 33

2%

1/39

11,31,33

2%

1/39
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APPENDIX D
HISTOMORPHOLOGY OF HPV DNA POSITIVE PAPILLOMAS
Feature

HPV DNA Positive

Cases

Acanthosis

89%

35/39

Koilocytosis

87%

34/39

Basal Cell Replication

87%

34/39

Parakeratin

41%

16/39

Hyperparakeratin

20%

8/39

Ortho/parakeratin

20%

8/39

Basal Cell Mitosis

12%

5/39

Hyperorthokeratin

7%

3/39

Hyperpara/parakeratin

5%

2/39

orthokeratin

5%

2/39

Dyskeratosis (benign)

5-%

2/39

Suprabasal Cell Mitosis

5%

2/39

Basal Cell Nuclear Hyperchromasia

2%

1/39

Basal Cell Prominent Nucleoli

2%

1/39

Multiple Nucleoli Supra/Basal Cell

2%

1/39
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APPENDIX E
HISTOMORPHOLOGY OF HPV DNA NEGATIVE PAPILLOMAS
Feature

HPV DNA Negative

Cases

Acanthosis

87%

21/24

Basal Cell Replication

66%

16/24

Koilocytosis

58%

14/24

Hyperparakeratin

37%

9/24

Parakeratin

29%

7/24

Orthokeratin

16%

4/24

Suprabasal Cell Replication

12%

3/24

Basal Cell Mitosis

8%

2/24

Hyperortho/parakeratin

8%

2/24

Hyperorthokeratin

4%

1/24

Hyperortho/orthokeratin

4%

1/24

Basal Cell Prominent Nucleoli

4%

1/24
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